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ABSTRACT  
 
Janet Berrios: Maternal UBE3A is required for neurotypical motivational drive and 
GABA co-release 
(Under the direction of Benjamin D. Philpot) 
 
 Dopaminergic projections from the ventral tegmental area (VTA) to the 
nucleus accumbens (NAc) are known to be critical players in motivated, reward-
seeking behaviors and are involved in learning processes during positive-
reinforcement. These neurons co-release several neurotransmitters in the NAc, 
however; their differential role in motivation and positive-reinforcement is unknown.  
Angelman syndrome (AS) is a neurodevelopmental disorder caused by the deletion 
or mutation of the E3-ubiquitin ligase, Ube3a.  Ube3a is monoallelically expressed 
from the maternal allele and is paternally imprinted in a tissue specific manner. 
Mouse models of AS have been shown to have dopaminergic related phenotypes 
such as ataxia and decreased brain stimulation reward (BSR) threshold.  This 
decrease in BSR is thought to be mediated, in part, by an increase in dopamine 
release within the NAc as evidenced within AS model mice using electrically 
mediated BSR. Because of this increase in dopamine release within the NAc, we 
hypothesized that VTA-to-NAc projections were hyperexcitable leading to 
dopaminergic dysregulation.   We used a combinatorial approach of in vivo and in 
vitro optogenetics to determine if dopaminergic projections from the VTA-to-NAc 
were specifically driving an increase in motivational drive and dopamine release.  
iv 
 
 Using circuit-specific manipulations, we found that there was not a change in 
dopamine release in AS model mice, but that there was a significant increase in 
motivational drive to self-stimulate these VTA axons in the NAc using a 1:1 
fixed-ratio operant task.  Next, we determined if Ube3a is required for neurotypical 
motivational drive using a novel conditional deletion mouse model (Ube3aFLOX/p+) in 
which Ube3a was deleted from tyrosine hydroxylase (TH) positive neurons. We 
found that upon conditional Ube3a deletion, dopamine release remained at similar 
levels to wildtype mice however, motivational drive was significantly increased to a 
similar degree as in AS model mice.  
 We then hypothesized that the change in motivational drive was mediated by 
GABA or glutamate co-release.   Previously, an inhibitory imbalance phenotype was 
found in AS model mice in which they have a decrease in inhibitory drive. We used 
in vitro optogenetics in conjunction with electrophysiology to determine if GABA and 
glutamate co-release was affected when Ube3a is specifically ablated in TH-positive 
neurons.  We found that GABA co-release was severely compromised when Ube3a 
is ablated but glutamate co-release was unaffected. We also found that these 
phenotypes can be rescued upon exogenous expression of VGAT, a vesicular 
GABA transporter.  
Here, we suggest a novel role for GABA co-release in VTA-to-NAc terminals 
in a mouse model for Angelman syndrome.  Using in vivo and in vitro optogenetic 
combinatorial approaches, our findings suggest a new utility for the E3-ubiqutin 
ligase, Ube3a, in inhibitory transmission from dopaminergic fibers in the ventral 
striatum.  
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CHAPTER 1  
 
 
 
 
INTRODUCTION 
 
 The aim of this dissertation project was to address the hypotheses that the 
gene, Ube3a, (i) is a potential molecular regulator of motivational drive, (ii) causes 
hyperexcitability in reward circuitry within Ube3a deficient mice, and (iii) is not 
directly involved in dopamine release from ventral tegmental area projections to the 
nucleus accumbens.  To address these hypotheses I employed a combinatorial 
approach of in vivo and in vitro optogenetics along with in vitro electrophysiology, in 
vitro fast-scan cyclic voltammetry, and operant conditioning paradigms.  
 As an introduction to this subject matter, subsections have been organized to 
provide a review of the applicable topics that include: (i) Angelman syndrome and 
mouse models of Angelman syndrome including the pathogenesis and phenotypes 
shared between mice and humans, (ii) neural circuits involved in reward-seeking and 
motivational drive including neurotransmission that has been defined as motivational 
regulators, and (iii) dopaminergic phenotypes that have been identified in other 
neurodevelopmental mouse models.  
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1.1 Angelman Syndrome: identification and known pathogenic molecular 
players 
 
1.1.1 The discovery and early characterization of Angelman syndrome  
Angelman syndrome (AS) was first described by Harry Angelman in 1965 in 
which he identified four key features in addition to severe developmental delay:  flat 
occiput, tremulous movement, protruding tongues, and frequent laughter (Angelman, 
1965).  Because of these core features, he first described AS as “happy puppet 
syndrome.” Principal features associated with AS have now been expanded and 
include an exhaustive list of associated phenotypes including (but not limited to): 
severe developmental delay, ataxia, frequent laughter, lack of speech, seizures, 
abnormal EEG, abnormal sleep-wake cycles, and tremors in adulthood (Williams et 
al., 2006).   
 
1.1.2 Genetic causes of AS 
AS has a penetrance of 1 in 12,000 and is a single gene disorder associated 
with the 15q11-13 chromosome that was first identified in 1987 (Clayton-Smith, 
2003; Mabb et al., 2011; Williams et al., 2006). 15q11-13 (UBE3A) is known to be 
genetically imprinted, or silenced, on the paternal allele by a region known as an 
imprinting center. Genetic mutations and deletions associated with AS have been 
categorized into four different groups.  These groups range from (i) de novo 
mutations, (ii) imprinting deficits leading to mutations or deletions, (iii) mosaic 
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imprinting deficits, and (iv) Ube3a mutation or deletion, a gene that is encoded by 
15q11-13 (Clayton Smith and Laan., 2003).   
 
1.1.3 The pathogenesis of AS by a single gene, Ube3a 
UBE3A is a HECT (Homologous to E6-AP Carboxyl Terminus)-containing E3 
ubiquitin ligase that is encoded by the 15q11-13 chromosome. UBE3A was first 
identified as E6-Associated Protein (E6-AP) as a regulator of p53 protein expression 
in HeLa cells, assigning it an oncogenic role in human papilloma virus (HPV) (Talis 
et al., 1998).  E6, along with E6-AP (or UBE3A), transfers ubiquitin to the substrate, 
p53, and then targets this protein for proteasomal degradation.  This role for UBE3A, 
within heterologous cell lines, provided some mechanistic insight into the 
pathogenesis of AS which will be further described in section 1.1.4.   
The chromosomal region containing the gene Ube3a (15q11-13) was a 
known “hot-spot” for genomic imprinting or, silencing (Mabb et al., 2011; Matsuura et 
al., 1997; Nicholls and Knepper, 2001).  This epigenetic phenomenon of imprinting 
results in alleles that are either paternally or maternally expressed making 
parent-of-origin inheritance of each allele critical.  The paternal allele of Ube3a is 
regulated by differential methylation of a particular imprinting center -- the Prader-
Willi Syndrome Imprinting Center (PWS-IC) -- that is upstream of the Snurf and 
Snrpn promoter regions (Landers et. al., 2005).  The result of this differential 
methylation on the paternal allele is the transcription of the Ube3a-ATS (Antisense) 
that encodes for an RNA antisense transcript that silences the transcription of Ube3a 
from the paternal allele in cis (Landers et al., 2005; Mabb et al., 2011; Matsuura et 
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al., 1997).  The imprinting of the paternal allele renders the maternal Ube3a allele 
vulnerable to mutations that could result in a loss-of-function or dysregulation of 
UBE3A protein.  Intriguingly, this imprinting is conserved in mice as in humans 
lending to the feasibility of making mouse models mimicking the human heredity of 
Ube3a.   Using a mouse model in which the yellow-fluorescent protein (YFP) is 
knocked into the Ube3a locus (Ube3aYFP) it was discovered that Ube3a imprinting 
only occurs within post-mitotic neurons in the brain but is biallecially expressed 
within glia leading to cell type-specific expression of UBE3A within the brain (Dindot 
et al., 2008).  
 
1.1.4 Neuronal phenotypes and proposed substrates of UBE3A 
The AS field, in regards to described neuronal phenotypes, began with the 
engineering of an AS model mouse by Yong-hui Jiang that contained a targeted 
deletion at exon 2 (Jiang et al., 1998).  This targeted disruption of Ube3a resulted in 
a null allele.  Since maternal Ube3a is the allele that is expressed in neural tissue, it 
is of utmost importance to note parent-of-origin inheritance for the null allele.  
Therefore, all AS model mice are maternally deficient for Ube3a while the paternal 
allele remains intact.  Because of the paternal imprinting, this renders the animal null 
for all neuronal UBE3A expression and AS model mice are denoted as: Ube3am–/p+.   
The first phenotypes described within Ube3am–/p+ involved motor dysfunction, 
long-term potentiation (LTP) deficits, and upregulation of p53, a previously identified 
UBE3A substrate (Jiang et al., 1998).  Ube3a-deficient mice were engineered by 
targeting exon 2 which deletes a portion of the N-terminal amino acids that 
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inactivates UBE3A protein.  This seminal paper and novel mouse line spawned a 
new opportunity for neuroscientists to elucidate circuit deficits in a rare 
neurodevelopmental disorder.  Neuronal phenotypes that have been described using 
this mouse line include (but are not limited to): decreased dendritic spine number 
and altered morphology (Dindot et al., 2008; Sato and Stryker, 2010; Yashiro et al., 
2009), experience dependent plasticity deficits (Sato and Stryker, 2010; Yashiro et 
al., 2009), altered intrinsic membrane properties (Kaphzan et al., 2011), loss of 
inhibitory drive correlated to an increase in clathrin coated vesicles (Wallace et al., 
2012), decreased locomotion (Huang et al., 2013; Riday et al., 2012), aberrant 
dopamine release (Riday et al., 2012), and dysregulation in circadian rhythm (Shi et 
al., 2015).  
While a rich literature describing circuit and synaptic deficits within AS model 
mice has matured, there is still little information on potential substrates of UBE3A 
that leads to the development of these observed neuronal phenotypes. As previously 
mentioned, UBE3A was first identified as E6-Associated Protein in that it required an 
oncogenic cofactor (E6) to degrade p53.  Because UBE3A is an E3-ubiquitin ligase, 
substrate identification has centered on identifying potential neuronal substrates by 
assessing correlated protein upregulation (Mabb et al., 2011).  Neuronal substrates 
that have been identified have done so by using co-immunoprecipitations and differ 
based not only on cellular localization but also anatomically.  The proposed UBE3A 
substrates are: p53, p27, Pbl, α-synuclein, Arc, Ephexin5, and GAT1 (Egawa et al., 
2012; Mabb et al., 2011).   
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Interactions within the proteomic pathway are fairly quick (within minutes) and 
are composed of weak thioester covalent bonds (Cooper et al., 2004; Martinez-Noel 
et al., 2012).  In addition, there are five subtypes of three different UBE3A isoforms, 
that differ within the N-terminus, leading to additional difficulty in identifying neuronal 
specific roles in anatomically distinct regions (Yamamoto et al., 1997).  Because of 
the mechanism of action, the ubiquitin proteolysis pathway is, in itself, transient in 
that these complexes will be degraded within the proteasome.  Biochemical 
analyses of complexes have therefore, been performed under conditions inhibiting 
the proteasome with MG132 (Cooper et al., 2004; Martinez-Noel et al., 2012; 
Yamamoto et al., 1997).  These factors as a whole have, therefore, made the 
identification of a true neuronal-specific substrate difficult.   
 
1.1.5 Dopaminergic phenotypes correlated with Ube3a loss 
There are phenotypes present within AS patients that can be ascribed to 
dopaminergic dysfunction.  These symptoms include ataxia and tremors that have 
been characterized as early-onset Parkinson’s (Harbord, 2001; Riday et al., 2012).  
The presence of these symptoms have led to the hypothesis that dopaminergic 
dependent circuits are affected in AS patients and have led to the use of levodopa 
(L-DOPA) in clinical trials (Harbord, 2001); Tan W-H, in progress).  While the use of 
L-DOPA in two elderly AS patients ameliorated tremors, it remained unclear as to 
how these symptoms arose (Harbord, 2001). In 2010, the Jana group suggested that 
the loss of Ube3a resulted in a loss of TH positive (TH+) neurons in the substantia 
nigra compacta (SNc) leading to the motor phenotypes observed in AS model mice 
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(Mulherkar and Jana, 2010).  However, this work does not take into account that the 
loss of TH+ neurons does not necessarily coincide with a decrease in dopamine (DA) 
release or directly relate to behavioral phenotypes. In drosophila, it was identified 
that UBE3A associates with GTP cyclohydrolase the rate limiting factor in 
monoamine synthesis (Ferdousy et al., 2011).  This work was further expanded 
upon in AS model mice by using microdialysis to measure the concentration of DA, 
serotonin, and norepinephrine within the striatum, midbrain and frontal cortex 
(Farook et al., 2012). Using this technique, an increase in catecholaminergic and 
serotoninergic concentration were found, however, microdialysis is only sufficient to 
measure extracellular concentration averaged across several minutes and does not 
take into account release mechanisms that occurs on a millisecond timescale.  
The proposed dopaminergic phenotypes had only been correlated with 
changes in dopamine release and have not been shown to have a causal 
relationship.  In addition, these were attributed to a decrease in release.  In 2012, 
Riday et. al. used a combinatorial approach of behavior, in vivo fast-scan cyclic 
voltammetry, and biochemistry to assess dopamine content and release in AS model 
mice using a behavioral paradigm known to be dopamine dependent.  Fast-scan 
cyclic voltammetry (FSCV) is the highest resolution method currently available to 
detect dopamine release in vivo and in vitro (Jones et al., 1996; Robinson et al., 
2003) and can be used to detect changes in DA release with nanomolar precision in 
a subsecond timescale.  Using in vivo FSCV, an opposing dysregulation in DA 
dynamics was found within AS model mice.  Within the nigrostriatal pathway (SNc-
to-dorsal striatum), voltammetric recordings revealed that there was a decrease in 
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electrically-evoked DA release in Ube3a-deficient mice and an increase within the 
mesolimbic pathway (VTA-to-NAc). This evidence corroborates previous 
publications suggesting that there is a decrease in DA within AS model mice that 
leads to motor deficits however, it was unknown how an increase would affect 
behaviors associated with the mesolimbic pathway.  Interestingly, Riday and 
colleagues also validated that there was not a difference in the number of TH+ 
neurons or dopamine tissue content in AS model mice when compared to controls 
which is in contrast to the previously described increase in catecholaminergic 
concentration (Farook et al., 2012; Mulherkar and Jana, 2010; Riday et al., 2012).    
Intracranial self-stimulation (ICSS) is behavior paradigm that has been 
classically used to determine reward-threshold via electrical stimulation and is often 
referred to as brain stimulation reward (BSR) (Olds and Milner, 1954).  This method 
of stimulation causes DA release and is essential to elicit synthetic “rewarding” 
behaviors.  Accumbal DA release is associated with the euphoric effects associated 
with drugs of abuse (e.g. opioids, cocaine) as well as food and copulation (Fields 
and Margolis, 2015; Wise and Rompre, 1989). By placing a stimulating electrode 
within the medial forebrain bundle (MFB), this ICSS paradigm was used in AS model 
mice to test the hypothesis if the increase in electrically-evoked DA release found 
with FSCV resulted in an expected behavioral consequence.  Indeed, Ube3am–/p+ 
mice had a lower threshold to maintain the BSR response and responded more over 
time, consistent with the increase in DA release within the NAc.  These results are 
intriguing and represent the first direct evidence for a change in DA release within 
AS model mice that has a direct behavioral consequence.  However, there is one 
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caveat that should be considered.  The stimulating electrode used for both the ICSS 
paradigm and FSCV was placed within the MFB.  The MFB contains axons that are 
heterogeneous and do not only project to the VTA but to other structures that will 
result in DA release within the NAc (Tsai et al., 2009).  Therefore, observed changes 
in DA release using MFB stimulation are not necessarily due to DAergic 
neuron-specific excitation but may occur through additional circuit mechanisms.  
 
 
1.2 Circuitry underlying reward-seeking and motivation 
 
1.2.1 The identification of “pleasure centers” and dopamine as a 
rewarding   neuromodulator 
Neural circuits responsible for regulating motivation are necessary for 
survival.  An animal must identify what behaviors should be repeated in order to gain 
access to pleasurable “rewards” such as sex, food, and social interaction.  Olds and 
Milner (1954) hypothesized that there are “pleasure centers” of the brain and used 
BSR in various brain regions to assay which areas supported self-stimulation in 
mice.  Their research identified a circuit responsible for “reward-seeking” by 
identifying anatomical regions responsible for the learning process that lead to 
positive-reinforcement which is, in part, mediated by dopamine (Robinson and 
Berridge, 1993; Schultz, 1998; Wise, 1978).  The effect of dopamine as a reinforcing 
neuromodulator was first identified by lesioning selective anatomical regions in 
parallel.  The use of BSR and the application of drugs of abuse, such as cocaine 
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(Schultz, 1998), helped in the identification of DA as a rewarding neuromodulator. 
The mesolimbic pathway, which is composed of projections from the VTA to the 
NAc, is the most well defined circuit involved in reward-seeking/motivational 
behavior.   
 
1.2.2 The VTA: cell types, projections, and electrophysiological 
properties 
The VTA, along with the SNc, is a major source of DA to the cortex and a 
majority of subcortical regions (Bjorklund and Dunnett, 2007; Bromberg-Martin et al., 
2010).  Neurons in the VTA are heterogeneous in cell types; most neurons are 
dopaminergic (~70%), and there are also GABAergic (~30%) interneurons, and a 
small percentage of glutamatergic neurons (~2%) (Nair-Roberts et al., 2008; Walsh 
and Han, 2014; Yamaguchi et al., 2007).   The VTA sends a majority of its 
dopaminergic projections to the NAc but it is important to note that the VTA also 
sends dopaminergic projections to the prefrontal cortex (PFC), central amygdala 
(CeA), basolateral amygdala (BLA), and hippocampus (Russo and Nestler, 2013; 
Walsh and Han, 2014).   In addition to the cell type heterogeneity within the VTA, 
dopaminergic neurons are now known to release several neurotransmitters in 
addition to dopamine, including GABA and glutamate (Stuber et al., 2010; Tritsch et 
al., 2012).   
Dopaminergic neurons fire in two distinct patterns that have been 
characterized as tonic and phasic firing rates which differ in frequency. Tonic firing 
rates are low in frequency (1-5 Hz) and are maintained at a steady baseline level 
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which results in a basal level of available dopamine in target structures that is 
required for neurotransmission in those terminal fields (Bromberg-Martin et al., 2010; 
Grace, 1991; Grace et al., 2007; Grace and Onn, 1989; Lammel et al., 2008; 
Schultz, 2007; Tsai et al., 2009; Yim and Mogenson, 1980). Phasic firing rates are 
increased to >15 Hz and are triggered by external stimuli that signal the presence of 
reward and cause a large increase in DA concentration in downstream targets 
(Schultz, 1998; Tsai et al., 2009).   
Identifying dopaminergic neurons within the VTA was previously simplified by 
looking at two distinct electrophysiological properties: the presence of an Ih 
(hyperpolarization-activated cyclic nucleotide-gated) current and intrinsic membrane 
properties that were first described within the SNc (Margolis et al., 2006).  Because 
the SNc is adjacent to the VTA, and the neuronal composition is fairly homogenous 
(~90% dopaminergic) an assumption was made that the electrophysiological 
properties defined for TH+ neurons within the SNc would apply to those in the VTA.  
However, Margolis et. al. determined that selecting for neurons in this fashion, within 
the VTA, results in inaccurate selection of DA containing neurons. Past hypotheses 
proposed that selecting for neurons with the presence of a pronounced Ih current is 
indicative of dopamine content.  In contrast, thorough electrophysiological and 
molecular characterizations have shown that those cells with larger Ih currents are 
likely TH-negative and that the size of the current differs based on the downstream 
targets of those TH+ projections (Ford et al., 2006; Margolis et al., 2006). In addition 
intrinsic membrane properties, action potential (AP) threshold, AP peak, AP width, 
soma size, or anatomical location does not provide any distinguishing parameters 
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between TH+ and TH-negative cells (Margolis et al., 2006).  Another characteristic of 
VTA dopaminergic neurons that increases the difficulty of accurately identifying them 
is that their electrophysiological properties will differ depending on where they send 
projections to (Lammel et al., 2008; Lammel et al., 2011; Lammel et al., 2014).  
The challenge in identifying dopaminergic neurons within the VTA comes in 
the heterogeneity of responses.  DA neurons that are within the medial VTA project 
to the mPFC, BLA, and NAc (core and shell). These neurons have little to no Ih, fire 
APs at high frequencies averaging 20-30 Hz, have broad action potentials and small 
after hyperpolarization, and have synapses with a high AMPAR/NMDAR 
conductance ratio (~0.6) (Lammel et al., 2014). DA neurons that have been shown 
to project to the NAc lateral shell are within the lateral VTA and have characteristic 
electrophysiological properties that were initially defined as: prominent Ih, AP firing 
frequencies up to 10 Hz, short AP half-width with  large after hyperpolarizations and 
a low AMPA/NMDA ratio (~0.4) (Lammel et al., 2014).  Because of the heterogeneity 
present in DA neurons within the VTA, there are several tools that have become 
necessary when selecting DA neurons for electrophysiology.  These tools include 
post-hoc immunohistochemistry, RetroBeads (LumaFluor), fluorescently labeled 
cholera toxin, fluorescently coupled transgenic lines (e.g. TH-EGFP), and CRE 
dependent reporters (e.g. Ai9, Ai6, Ai3, etc.).   
Each of these tools, however, come with their own set of caveats.  Post-hoc 
immunohistochemistry will reliably label TH+ cells however will result in 
false-negatives in neurons which have undergone extensive whole-cell recording 
times (Margolis et al., 2006).  RetroBeads allows the user to surgically inject a 
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fluorescently labeled microsphere within a region of interest.  These beads will then 
be transported in a retrograde fashion, which allows the user to select cell bodies of 
interest in the appropriate projection neurons.  This trafficking takes time, however, 
and the user must wait weeks for the RetroBeads to travel to the cell bodies of 
interest.  Fluorescently-labeled cholera toxin is another form of retrograde labeling 
that requires surgical intervention. Viral expression, however, is quick (on the order 
of days) but is toxic to cells over a long period of time.  The advent of mouse 
reporter lines have allowed for the engineering of promoters of interest (e.g. TH and 
DAT) to be fused with fluorescent reporters which are long lasting within the mouse 
in vivo.  Transgenic reporters, along with other reporter lines that are CRE 
dependent such as the Ai9 reporter (STOP-floxed-tdTomato), allow the user to 
combine a CRE line of interest to fluorescently label those cells upon recombination.  
There are a few considerations when selecting a CRE line for experimental use, 
once being that once the CRE has performed the recombination event, those cells 
will express the fluorophore for the lifetime of the animal and thus the expression of 
the reporter may not be representative of protein expression at the time the animal is 
sacrificed.  In addition, the THCRE lines have come under much scrutiny as of late 
and it has been shown that THCRE lines exhibit low dopamine specificity whereas the 
DATCRE lines exhibit high dopamine specificity within the ventral midbrain (Lammel 
et al., 2015).  Using a combinatorial approach of cell-type specific selection along 
with anatomical boundaries provides the best current approach for selecting DA 
neurons for electrophysiological characterizations.   
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1.2.3 Dopaminergic activity during reward and aversion 
A topic of increasing interest is how DA efferents originating in the VTA 
encode two distinct behaviors: motivational salience/value and avoidance.  
Dopaminergic neurons have been classically defined to have a role in “reward-
prediction error” that aids in positive-reinforcement learning (Schultz, 2007).  
Wolfram Schultz found that if a reward is larger than predicted, then DAergic 
neurons are strongly excited, but, if a reward is smaller than predicted then DAergic 
neurons are inhibited.  In addition, if a reward is just as predicted, then this has no 
consequence on DA release.  Moreover, DA neurons encode for “temporal 
difference error” (TDE) that is essential for positive-reinforcement learning and takes 
external sensory cues into account (Bromberg-Martin et al., 2010).  In the case of 
TDE, DA neurons are excited when an external cue designates an increase in the 
value of a future reward; neurons are inhibited when an external cue designates a 
decrease in value of a future reward; and have little to no response when an external 
cue does not convey any new information for a future reward (Bromberg-Martin et 
al., 2010; Montague et al., 1996).  In regards to motivational value and salience, 
reward and avoidance are often coupled together.  For instance, if an animal is 
reward-seeking it has assigned a positive value to that reward but, if a reinforcing 
cue is aversive, it has assigned negative value to that cue.  This has been defined 
as motivational value whereas, motivational salience refers to the attending of 
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particular cues that triggers the cognitive process for reward-seeking or avoidance 
(Bromberg-Martin et al., 2010).  
But how are these behaviors encoded on a neuronal level? With the advent of 
optogenetics, and the use of in vivo single unit recordings, circuit-level processing 
for these two behaviors is becoming elucidated.  In vivo electrophysiological 
recordings have shown that DA neurons change their firing frequency from a low, 
tonic frequency pattern to a high, phasic firing pattern to encode reward-prediction 
and motivational salience (Tsai et al., 2009).  In contrast, these neurons are inhibited 
upon the presence of an aversive stimulus.  While the correlation between DAergic 
activity and reward valence is tantalizing, these studies did not provide a causative 
link between the two.   Causal links were first established using optogenetic 
approaches.  For example, Tsai and colleagues performed experiments in which 
they injected a CRE dependent channel rhodopsin-2 (DIO-ChR2-EYFP) within the 
VTA of THCRE positive animals and tested them in a conditioned place preference 
paradigm (CPP).  ChR2 allows for the precise control of the neurons of interest (on 
the order of ms) and in this case, provides the additional precision of manipulating a 
selected cell-type of interest (e.g. TH+).  This provided the first evidence that the 
activation of dopaminergic cell bodies alone results in behavioral conditioning by 
firing TH+ neurons at a phasic firing frequency (50 Hz).  In addition, this seminal 
paper illustrated that only phasic activation of TH+ neurons results in robust DA 
release (~76 nM) within the NAc whereas tonic stimulation (1 Hz) results in 
incredibly low amounts of DA release (~1.5 nM) that correlate with the optically-
evoked conditional place preference.   
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1.2.4 Targets of the VTA that promote reward-seeking: NAc, mPFC, and 
dorsal striatum  
The mesolimbic pathway has long been associated with reward-seeking 
behavior.  As mentioned in section 1.2.2, phasic DA bursts from the VTA in several 
regions of the ventral and dorsal striatum encode reward-seeking behavior.  
However, the VTA has also been implicated in encoding avoidance therefore, 
DAergic phasic bursts to particular targets play an important role in encoding 
behavioral output.  What are the differences within VTA target structures that encode 
these opposing behaviors?  The striatum is a heterogeneous structure that is 
composed of three major cell types: medium spiny neurons (MSN), cholinergic 
interneurons, and GABAergic interneurons.  Notably, the NAc is composed of 
approximately 95% MSNs that are further categorized by being either D1 or D2 
containing (Robison and Nestler, 2011).  D1 and D2 receptors have been shown to 
activate two different striatal circuits: the direct and indirect pathway, respectively.  
The direct pathway is known to play a key role in movement initiation, whereas the 
indirect pathway plays a role in inhibiting unwanted voluntary movements (Frank, 
2005).  The increase in DA concentration that results from phasic firing has been 
hypothesized to produce conditions of high available DA which preferentially 
activates D1 receptors and therefore causes activation of the direct pathway which 
facilitates movements towards a highly-valued reward (Bromberg-Martin et al., 2010; 
Frank, 2005).  In conditions where DAergic neurons are inhibited (e.g. low-valued 
rewards), available DA will be low, inhibiting D2-containing neurons and initiating 
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suppression of movement via the indirect pathway (Bromberg-Martin et al., 2010; 
Frank, 2005). Further evidence for this is seen in optogenetic mediated CPP that is 
enhanced by cocaine.  Optogenetic stimulation of D1 containing MSNs has shown to 
result in enhanced CPP when cocaine is on board whereas, stimulation of D2 
containing MSNs has the opposite effect (Russo and Nestler, 2013).  In addition, 
chronic administration of cocaine has been well described to have a role in structural 
and functional plasticity within MSNs, an effect that is illustrated by the increase in 
dendritic spine number and change in morphology (Russo and Nestler, 2013).  
There is a vast literature present on DAergic responses to reward from the VTA, 
however, there is still little evidence on how reward-seeking behavior is encoded to 
VTA accumbal targets.  What has come to light is that DA is most important when 
target neurons are most excitable but, has little consequence otherwise (Floresco, 
2015).  Therefore, instead of directly promoting reward-seeking, DA may potentially 
be responsible for augmenting responses from the VTA that are being driven 
additionally by upstream glutamatergic inputs such as the PFC, glutamatergic 
projections from the VTA, hippocampus, and BLA.  
The dorsal striatum, like the ventral striatum, is composed of MSNs that are 
mostly D1 and D2 containing.  Characteristically, this subdivision of the striatum is 
classified within the basal ganglia and has been extensively studied for its role in 
motor execution and planning. As briefly mentioned, these D1- and D2-containing 
MSNs compose the direct (“go”) and indirect (“no-go”) pathway, respectively.  
However, Keeler, Pretsell, and Robinson (2014) proposed a new, more specific role 
for these two pathways and defined it as the Prepare and Select (PAS) circuit 
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(Keeler et al., 2014).  This PAS circuit suggests that D1-expressing MSNs prepare 
the circuit for the possible motor actions that can be taken while the D2-expressing 
MSNs further refine this to achieve a respective goal.  D1 and D2 receptors have 
different binding affinities for DA.  D1 receptors have low binding affinity for DA and 
are therefore more sensitive to phasic dopamine release whereas, D2 receptors 
have high binding affinity for DA and are sensitive to tonic dopamine release (Dreyer 
et al., 2010; Keeler et al., 2014; Surmeier et al., 2007).  These MSNs accumulate 
inputs from multiple regions (excitatory and dopaminergic) to then dictate a 
behavioral consequence.  Each are responsive to DA, so how are these two distinct 
neuron types that respond to the same neuromodulator promote separate behavioral 
outcomes?  The “race” hypothesis takes these binding affinities into account and 
proposes that D1 activation reduces the firing threshold which activates the “go” 
pathway preferentially; D2Rs are inhibitory and will therefore increase the input 
strength needed to activate the “no-go” pathway (Keeler et al., 2014).   Because 
D1Rs are preferentially activated, they will encode more salient information and 
promote faster reaction times (Keeler et al., 2014).  As an example, once an animal 
under goes training in an operant conditioning paradigm, the longer the animal has 
been undergoing training the faster reaction times will be even though the incoming 
sensory information is identical to previously experienced sessions.  Therefore, 
D1Rs are thought to be preferentially activated in the presence of a highly-valued 
reward which is correlated with high striatal activity mediated by stimulatory g-
coupled proteins.  Repeated phasic dopamine release causes D1 and D2 receptor 
internalization (Ostlund et al., 2011). High reward-value is also encoded by D2Rs (in 
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addition to D1Rs) via internalization mechanisms and is correlated by the presence 
of low D2R expression.  In the presence of a motivating stimulus (e.g. hunger or sex) 
tonic DA concentration is increased and will therefore, activate more D2Rs and in 
turn cause their internalization, biasing reward-seeking via D1R activation upon the 
presentation of a reward (Dreyer et al., 2010; Rice and Cragg, 2008).  
The mesocortical pathway is composed of projections from the VTA to the 
PFC.  These dopaminergic projections also have a long standing association with 
the reward-seeking pathway.  However, these DA projections are not intrinsically 
rewarding per se but rather regulate essential circuits that are imperative for 
motivation such as higher-order motor control, motivation, and cognition (Seamans 
and Yang, 2004).  DA release within the PFC is not related to reward-prediction error 
as in the NAc but rather plays an important role when the animal is performing the 
task.  For instance, in a delayed response task, DA is released at the beginning of 
the task and is maintained during the performance of the task, suggesting that DA is 
required for the encoding and the use of working memory but is not necessary for 
retention of the task or to encode reward-value (Seamans and Yang, 2004).  In 
primates, in vivo single-unit recordings in conjunction with microinontophoresis have 
provided empirical evidence that DA levels are the highest within the PFC during the 
delayed-period and that this effect of DA was mediated by D1 receptors specifically 
(Sawaguchi and Goldman-Rakic, 1994; Seamans and Yang, 2004).  Lammel et. al. 
(2008) suggested that the VTA neurons which project to the PFC arise from a 
unique population within the medial posterior PFC and exhibit different 
electrophysiological properties as described in section 1.2.2.   In addition to the PFC 
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participating in reward-seeking by modulating working-memory, the PFC also plays 
an integral part in the extinction of a learned behavior associated with a reward 
(Sparta et al., 2014) that also consists of an active learning process. The mPFC is 
known to play a role in both appetitive and aversive conditioning and is the crucial 
circuit node for the expression and extinction of cue-mediated behaviors.  Sparta 
and colleagues showed that this is a phenomenon that is likely mediated by 
parvalbumin positive fast-spiking interneurons (Sparta et al., 2014).  The 
mesolimbic, mesocortical, and striatal circuits are therefore integral nodes for the 
expression, execution, acquisition, and extinction for motivation and reward-seeking. 
 
1.2.5 Newly appreciated roles of dopamine and basal ganglia circuitry  
Dopamine is the neuromodulator most strongly linked to reward prediction 
error (Schultz, 1998).  However, basal ganglia / dopaminergic circuitry have also 
been strongly linked to reinforcement learning.  Reinforcement learning, in the 
greater context of basal ganglia circuitry, is based on two different models of 
evaluation:  model-based and model-free (Huys et al., 2015).  Model-based 
evaluation is built on an animal’s ability to create a probabilistic model of the world, 
which takes into account how predictive outcomes vary with the particular course of 
actions (Huys et al., 2015; Laurent and Balleine, 2015).  On the other hand, model-
free evaluation factors in how motivational states can introduce prediction errors that 
influence the ability to assess the long-range outcomes; chanegs in phasic 
dopamine release can alter these prediction errors  (Huys et al., 2015).  Taking 
these two models into account, goal-directed behavior has four separate elements: 
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(1) evaluation (e.g. value of an action), (2) execution (e.g. choosing an action), (3) 
acquisition (e.g. learning to perform so an action can be taken), and (4) interruption 
(e.g. interrupting a previously acquired behavior when a better alternative is 
available) (Laurent and Balleine, 2015).  Three distinct basal ganglionic loops 
execute the four elements of goal directed behaviors. These loops are (i) motor 
loops, which initiates motor commands and occurs in both model-free and model-
based evaluation. The (ii) cognitive loop, which plans actions and also occurs in both 
model-free and model-based evaluation.  Lastly, the (iii) limbic loop which permits an 
action to be implemented given the motivational state of the animal.  The pattern and 
amount of dopamine release influence the outcomes of these basal ganglionic loops, 
such that tonic dopamine release is thought to influence the utility of an action within 
these cases whereas, phasic dopamine release is thought to modulate 
reinforcement learning on a model-free basis (Huys et al., 2015; Laurent and 
Balleine, 2015).  
In addition to the role of dopaminergic basal ganglia circuitry in goal directed 
behaviors, dopamine also has been shown to affect depressive mediated behaviors.  
Because DA has a long known role in reward-related motivational behaviors, Tye 
and colleagues used a cell type-specific excitation and inhibition of dopaminergic 
neurons to elucidate a mechanisms for bidirectionally modulating depressive 
symptoms (e.g. a decrease in escape behavior and sucrose consumption) (Tye et 
al., 2013).  Conversely, channelrhodopsin-mediated excitation of VTA DA neurons 
increased escape attempts and sucrose consumption, suggesting that phasic 
dopamine bursts in the NAc are needed for escape-related behaviors.  These 
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findings were the first to suggest an immediate role for phasic dopamine release in 
the bidirectional modulation of depressive symptoms caused by stressors, such as in 
a tail-suspension assay (Tye et al., 2013). 
 
1.3 Dopaminergic phenotypes characterized neurodevelopmental 
models  
 Impaired social interactions, language deficits, and repetitive stereotyped 
behaviors are core phenotypes associated with autism (Geschwind and Levitt, 
2007). Within these ascribed phenotypes, the hormone oxytocin has been elucidated 
to be an important social reinforcement signal within the NAc core (Dolen et al., 
2013) and that polymorphisms of oxytocin receptors are associated with autism.  
While these findings do not directly implicate dopamine within autism spectrum 
disorders, they do provide novel contextual evidence for a decrease in appetitive 
(social) behavior within autism models that are mediated by D1/D2 receptor 
containing MSNs.  However, many of the dopaminergic pathway dysfunctions 
characterized have centered on those phenotypes that are related to repetitive 
stereotyped behaviors and motor impairments.  One intriguing finding was presented 
by the modeling of a single point mutation found within the human DAT (dopamine 
transporter) protein that is associated with ASD (Hamilton et al., 2013).  The de novo 
missense mutation within hDAT (T356M) causes reverse transport of DA which 
results in an efflux and correlates with a potential increase in available extracellular 
DA which could account for some of the psychiatric symptoms seen in patients with 
ASDs (Hamilton et al., 2013).  
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 1.3.1 Mouse models of 16p11.2 loss  
 16p11.2 is a common chromosomal mutation that has been associated with 
autism spectrum disorders (Portmann et al., 2014).  Patients presenting with this 
chromosomal mutation have phenotypes much like those described within AS such 
as: motor deficits, speech/language delay, and severe cognitive impairments.  
Interestingly a duplication in 16p11.2 has been associated with schizophrenia 
(McCarthy et al., 2009; Portmann et al., 2014).  The Dolmetsch group engineered a 
novel mouse line exhibiting a mutation within the syntenic region to the human 
homolog (Portmann et al., 2014).  Using this neurodevelopmental mouse model, the 
deletion in 16p11.2 caused anatomical (within striatum and cortex) and 
neurophysiological abnormalities that could be correlated to motor dysfunction.  
These anatomical abnormalities included an increase in the number of D2 containing 
MSNs while exhibiting a decrease in D1-containing MSNs with no change in 
dendritic spine number.  These 16p11.2 deletion mice exhibited a number of 
physiological changes specific to D2 containing MSNs including: increase sEPSC 
frequency, decrease paired pulse ratio (PPR), increase AMPA/NMDA ratio, and an 
increase in mEPSC frequency.  Behavioral phenotypes that correlate with striatal 
dysfunction include decreased startle response, lack of movement fluidity, frequent 
tremor, frequent circling, and a decrease in exploration in an open-field context.   
Further validation of the D2R mediated effect was shown by the lack of an effect 
these mutant mice exhibited to pharmacological D2 antagonism.  Overall, these 
results indicate that the loss of 16p11.2 results in anatomical changes that directly 
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affects motor dysfunction and is mediated by the loss of D1R containing MSNs and 
loss of Darpp-32, an integral DA signaling component.   
 
 1.3.2 Neuroligin-3 mutations associated with striatal dysfunction 
 Neuroligin is a post-synaptic cell-adhesion protein that modulates the 
formation of synapses.  Mutations in neuroligin-3 (NL3) are associated with autism in 
humans and synaptic deficits in mice (Rothwell et al., 2014).  There are several 
mouse models with various NL3 mutations that have no overlap in synaptic 
phenotypes but exhibit the same enhanced repetitive motor routines that are due to 
cerebellar or striatal deficits but not due to synaptic impairment within the NAc 
(Rothwell et al., 2014).  Conditional deletion of NL3 in D1- and D2-containing MSNs 
increased rotorod learning by specifically impeding synaptic inhibition onto accumbal 
D1-containing MSNs but not D2-containing neurons.  NL3 mutant mice had a 
decrease in intrinsic excitability, and increase in rheobase, and a decrease in 
AMPA/NMDA ratio in D1-containing MSNs (Rothwell et al., 2014).  While these 
phenotypes were characterized within basal ganglia circuitry that receive robust 
dopaminergic inputs, they are not indicative of a direct dopamine deficiency.  
 
 1.3.3 Dopaminergic associated phenotypes in Rett syndrome  
 Mutations in MeCP2 (methyl CpG binding protein-2) causes Rett syndrome, 
an x-linked disorder that exhibits Parkinsonian-like tremors which is suggestive of 
nigrostriatal dysregulation (Gantz et al., 2011). This is evidenced by observing 
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conditional loss of MeCP2 within TH+ neurons that is known to reduce locomotion 
(Samaco et al., 2009).  Early in development (postnatal day 30), MeCP2 negative 
neurons exhibited decreases in dendritic length, resting membrane potential, and 
capacitance that was maintained in mature adults (> postnatal day 60) within the 
dorsal striatum. In addition, these neurons exhibited neurotypical D2R expression 
but altered D2R activation and a loss of DA release as measured by fast-scan cyclic 
voltammetry (Gantz et al., 2011).  
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CHAPTER 2 
 
 
LOSS OF UBE3A FROM TH-EXPRESSING NEURONS SUPPRESSES GABA 
CO-RELEASE AND ENHANCES REWARD-SEEKING BEHAVIOR1 
 
2.1 Overview 
Motivated reward-seeking behaviors are governed by dopaminergic ventral 
tegmental area projections to the nucleus accumbens.  In addition to dopamine, 
these mesoaccumbal terminals co-release other neurotransmitters including GABA, 
whose roles in regulating motivated behaviors are unknown.  Here we demonstrate 
that specific loss of the Angelman syndrome-associated UBE3A protein in tyrosine 
hydroxylase-expressing neurons does not affect dopamine release, but impairs 
mesoaccumbal GABA co-release and enhances reward-seeking behavior.   
 
2.2 Introduction 
Loss-of-function of the maternal UBE3A allele causes Angelman syndrome 
(AS), a severe neurodevelopmental disorder characterized by cognitive impairments, 
                                                           
1
 This chapter was submitted to Nature Neuroscience on April 20, 2015 with Alice M. 
Stamatakis,  Pranish A. Kantak, Zoe A. McElligott, Matthew C. Judson, Garret D. Stuber, 
and Benjamin D. Philpot.  
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epilepsy, lack of speech, and motor deficits (Williams et al., 2006).  Some AS 
patients exhibit symptoms consistent with dopaminergic dysfunction (Dichter et al., 
2012; Harbord, 2001), of which there is evidence in the mesoaccumbal pathway of 
AS model mice (Ube3am–/p+) (Riday et al., 2012).  Notably, Ube3am–/p+ mice exhibit 
increased electrically-evoked dopamine release within the nucleus accumbens 
(NAc) and correlated enhancements in reward-seeking behavior in response to 
electrical stimulation of the medial forebrain bundle (Riday et al., 2012), suggesting 
that UBE3A may directly regulate dopamine release from mesoaccumbal terminals.  
Alternatively, extracellular activation of heterogeneous, non-dopaminergic 
projections within the medial forebrain bundle might lead to differential dopamine 
release through complex circuit-level mechanisms (Robinson et al., 2003).  Here, we 
optogenetically interrogated putative roles for UBE3A in regulating neurotransmitter 
release from tyrosine hydroxylase-positive (TH+) mesoaccumbal terminals and, in 
turn, motivational drive.   
 
2.3 Results 
To target catecholaminergic neurons and the mesoaccumbal pathway, mice 
expressing CRE recombinase within TH+ neurons (THCRE) were crossed with 
Ube3am–/p+ mice or their wildtype littermates (Ube3am+/p+).  To specifically manipulate 
the axon terminals of NAc-projecting TH+ neurons, we transduced CRE-dependent 
AAV5-channelrhodopsin-2 fused to enhanced yellow fluorescent protein (ChR2-
eYFP) into the VTA and implanted an optical fiber in the NAc (Fig. 2.1a1).  We 
observed qualitatively similar viral expression within the CRE-expressing lines (Figs. 
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2.1a2, 2.2), but no expression following viral treatment in wildtype control mice. To 
determine how the loss of UBE3A affects reward-related phenotypes through TH+ 
neurons projecting to the NAc, we tested mice in a real-time place preference task 
across a range of optical stimulation frequencies (20, 30, and 40 Hz) (Fig. 2.3a).  
When mice crossed into the designated stimulation side, light was constantly pulsed 
until they crossed back into the other side (Stamatakis and Stuber, 2012).  
THCRE::Ube3am–/p+ mice showed a preference for receiving optical stimulation, 
regardless of stimulation frequency (Fig. 2.3a2-4). This preference was statistically 
greater than that of both THCRE::Ube3am+/p+ and wildtype mice at 30 Hz stimulation 
(Fig. 2.3a3), and furthermore, did not coincide with a change in movement velocity 
(Fig. 2.3b).  These data indicate that maternal Ube3a loss enhances reward-seeking 
behavior that is elicited by the selective optogenetic activation of TH+ VTA-to-NAc 
terminals.   
To determine if there are differences in positive-reinforcement behavior, we 
trained THCRE::Ube3am–/p+ and THCRE::Ube3am+/p+ mice to nose-poke for 30 Hz 
stimulation at a 1:1 fixed-ratio schedule. These mice similarly learned an appetitive 
nose-poke operant task (Fig. 2.3c).  However, THCRE::Ube3am–/p+ mice nose-poked 
to receive optical stimulation significantly more than THCRE::Ube3am+/p+ mice (Fig. 
2.1b).  These data suggest that the loss of UBE3A enhances motivation driven 
through TH+ terminals within the NAc, thus increasing reward-seeking.  
Based on previous findings (Riday et al., 2012), we hypothesized that UBE3A 
loss might enhance optically-evoked reward-seeking by increasing VTA-to-NAc 
dopamine release.  To examine this possibility, we performed in vitro fast-scan cyclic 
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voltammetry in brain slices from THCRE::Ube3am–/p+ and THCRE::Ube3am+/p+ mice 
expressing ChR2-eYFP within VTA-to-NAc terminals.  To probe for possible 
changes in dopamine release and quantal content, we optically stimulated either 
with a single pulse (Fig. 2.4a2) or with stimulation trains across a range of 
frequencies (Fig. 2.4a3).  Contrary to our initial hypothesis, the loss of UBE3A had 
no apparent effect on dopamine availability or release.  Moreover, using in vitro 
whole-cell electrophysiology, we found that intrinsic excitability and inhibition onto 
VTA neurons were unchanged in THCRE::Ube3am–/p+ mice compared to controls (Fig. 
2.5).  Collectively, these findings suggest that enhanced reward seeking in Ube3am–
/p+ mice is not due to changes in dopamine release from VTA-to-NAc dopaminergic 
terminals or due to altered excitability of dopaminergic VTA neurons in Ube3am–/p+ 
mice.  
Because VTA neurons exhibited typical excitability and retain a normal 
capacity to release dopamine in Ube3am–/p+ mice (Figs. 2.4-2.5), we questioned if 
maternal Ube3a deletion selectively in catecholaminergic neurons would be 
sufficient to alter motivational drive.  To test this, we used a novel conditional Ube3a 
knockout mouse (Ube3aFLOX) to selectively delete maternal Ube3a in a THCRE-
dependent manner (Fig. 2.2).  We injected THCRE::Ube3aFLOX/p+ and 
THCRE::Ube3am+/p+ mice with CRE-dependent ChR2-eYFP  into the VTA to determine 
if deletion of Ube3a within TH+ neurons would be sufficient to phenocopy reward-
seeking phenotypes observed in AS model mice. Mice were trained to nose-poke 
(as described above) for optical stimulation of CRE+ terminals within the NAc.  
THCRE::Ube3aFLOX/p+ mice poked significantly more for 30 Hz stimulation than 
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THCRE::Ube3am+/p+ mice (Fig. 2.6a).  This difference occurred in the absence of 
observable changes in optically-evoked dopamine release (Fig. 2.6b1-2).  These data 
demonstrate that the selective loss of UBE3A in TH+ neurons is sufficient to enhance 
motivational drive despite the lack of a detectable deficit in NAc dopamine release.  
In the NAc, dopaminergic terminals are capable of also releasing glutamate 
and GABA (Stuber et al., 2010; Tritsch et al., 2012; Tritsch et al., 2014; Zhang et al., 
2015). Thus, we tested whether Ube3a loss in TH+ neurons could alter transmitter 
co-release.  To assess this, we optogenetically activated VTA-to-NAc terminals and 
measured GABAergic currents in ventral striatal medium spiny neurons while 
blocking glutamatergic responses with AMPA and NMDA receptor antagonists (Fig. 
2.6c).  We applied a single light-pulse (20 ms) to measure peak amplitude and 
kinetics of the resulting current by averaging ≥ 6 consecutive traces (Fig. 2.6d1).  We 
confirmed post hoc that these currents were GABAR-mediated by bath applying 
SR95531, a selective GABA receptor antagonist (Fig. 2.6d1).  We found that 
GABAR-mediated currents in THCRE::Ube3aFLOX/p+ mice showed a >50% reduction in 
peak amplitude relative to controls but displayed normal decay kinetics (Fig. 2.6d2-3). 
Using an optical stimulation paradigm similar to that used in the behavioral 
experiments, we also found that THCRE::Ube3aFLOX/p+ mice exhibit diminished 
GABAergic currents at 30 Hz stimulation of VTA-to-NAc terminals compared to 
control mice (Fig. 2.6d4).    
Collectively, our data indicate that UBE3A regulates circuits involved in 
reward-seeking behavior and, in particular, GABA co-release from putative 
dopaminergic mesoaccumbal terminals.  Following UBE3A loss, suppressed GABA 
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co-release and enhanced reward-seeking behavior occur in the absence of other 
measured cellular and synaptic deficits in the mesoaccumbal pathway. This 
suggests that GABA co-release from VTA-to-NAc terminals may be causally linked 
to motivational drive in Ube3a-deficient mice. 
 
2.5 Materials and Methods 
 
2.5.1 Experimental Subjects and Stereotaxic Surgeries 
Cg-Tg-TH:Cre mice (JAX #: 008601), Rosa26-stop-floxed-tdTomato (Ai9, JAX 
#: 007909), and Ube3a-deficient (JAX #: 016590) mice were obtained through 
Jackson Laboratories. Ube3a-floxed mice were engineered in conjunction with the 
UNC Animal Models Core.  These mice were on a C57BL/6 background except for 
the Ube3a-floxed mice which were mixed with a 129S6:C57BL/6 background but 
backcrossed eight generations before experimental use. Mice were housed on a 
12:12 light-dark cycle. Mice for electrophysiological recordings were aged P60-P90 
and were compared to wild-type age- and sex-matched controls.  The experimenter 
was blind to genotype, and littermate controls were used when possible.  Behavioral 
mice were group housed until surgery and were taken at 25-30g (approximately 
P60).  Mice were anesthetized with ketamine (150mg/kg) and xylazine (50mg/kg), 
and then placed in a stereotaxic frame (Kopf Instruments) for bilateral injections 
(0.5µl) of purified adeno-associated virus (~1012 viral genomes/ ml, packaged and 
titered by the UNC Viral Vector Core Facility) into the VTA (coordinates from 
bregma: -3.15 anterior/posterior, ±0.75 medial/lateral, -4.75 dorsal/ventral). VTA 
32 
 
neurons in THCRE positive Ube3am–/p+, Ube3aFLOX/p+, or Ube3a+/+ mice were 
transduced with virus encoding ChR2-eYFP under the control of the EF1α promoter.  
Following surgery, mice were individually housed.  For behavioral experiments, mice 
were implanted with bilateral chronic fibers directed above the NAc (coordinates 
from bregma: +1.2 A/P, ±1.6 M/L, -4.6 D/V at a 10°angle). We performed all 
experiments 5-8 weeks post-surgery.  All procedures were conducted in accordance 
with the Guide for the Care and Use of Laboratory Animals as adopted by the 
National Institutes of Health, and with approval of the UNC Institutional Animal Care 
and Use committees.   
 
2.5.2 Slice preparation for whole-cell electrophysiology and voltammetry 
Mice were anesthetized with pentobarbital (40mg/kg) and intracardially 
perfused with ice-cold dissection buffer (in mM: 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 
NAHCO3, 75 sucrose, 10 dextrose, 1.3 ascorbic acid, 7 MgCl2 and 0.5 CaCl2) 
bubbled with 95% O2-5% CO2 after disappearance of corneal reflexes.  Brains were 
then rapidly removed and immersed in ice-cold dissection buffer.  VTA sections were 
dissected and 200µM horizontal slices were prepared using a vibrating microtome 
(Leica VT1200S).  NAc sections were dissected and 250µM coronal slices were 
prepared as described within the VTA.  Slices recovered for 20 min in a 35°C 
submersion chamber filled with oxygenated artificial cerebrospinal fluid (ACSF) (in 
mM: 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NAHCO3, 1 MgCl2, 2 CaCl2, and 20 
glucose) and then kept at room temperature for >40 min until use (Philpot et al., 
2003). 
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2.5.3 Voltage-clamp Recordings 
Spontaneous Inhibitory Postsynaptic Currents: To isolate spontaneous 
inhibitory postsynaptic currents (sIPSCs), slices were placed in a submersion 
chamber, maintained at 27°C and perfused at 2 ml/min with oxygenated ACSF (as 
described above) and held at the AMPAR reversal potential (+10mV).  AMPAR 
reversal potential was empirically determined by applying a series of 10 pA current 
injections (-70 to +60 mV) in the presence of picrotoxin and D,L-APV.  sIPSCs were 
confirmed post hoc by the addition of 10µM SR95531.  Cells were visualized using a 
Zeiss Examiner microscope equipped with infrared differential interference contrast 
(IR-DIC) optics. Putative VTA-to-NAc dopaminergic neurons were identified by 
tdTomato fluorescence medial to the medial terminal nucleus of the accessory optic 
tract in THCRE::Ai9::Ube3am–/p+  or wildtype mice. Patch pipettes were pulled from 
thick-walled borosilicate glass (P2000, Sutter Instruments Novato, CA).  Open tip 
resistances were between 2.5-5 MΩ and were back-filled with an internal containing 
(in mM): 100 CsCH3SO3, 15 CsCl, 2.5 MgCl2, 10 Hepes, 5 QX-314, 5 BAPTA, 4 Mg-
ATP, 0.3 Mg-GTP, and 0.025 Alexa-488 with pH adjusted to 7.25 with 1M CsOH and 
osmolarity adjusted to ~295 mOsm by the addition of sucrose.  Voltage-clamp 
recordings were performed in the whole-cell configuration using patch-clamp 
amplifier (Multiclamp 700B, Molecular Devices), and data were acquired and 
analyzed using pClamp 10 software (Molecular Devices). Pipette seal resistances 
were >1 GΩ, and pipette capacitive transients were minimized before breakthrough.  
Changes in series and input resistance were monitored throughout the experiment 
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by giving a test pulse every 30s and measuring the amplitude of the capacitive 
current.  Cells were discarded if series resistance rose above 30 MΩ. 
 
Optogenetic activation of THCRE::ChR2-eYFP fibers and measurement of 
GABA co-release:  Widefield ChR2 mediated photostimulation was provided through 
a 20X/0.8 NA objective using single-photon excitation through a 470 nm λ filter.  
Light power was provided by a Lambda DG-4 300 W Xenon bulb (Sutter 
Instruments).  This light was coupled to a Mosaic microelectro-mechanical-system 
digital micromirror device (Andor Technology) and was shuttered via pClamp 
mediated TTL pulse to the Lambda DG-4 as previously described (Larsen et al., 
2014).  GABA co-release from TH positive terminals originating in the VTA was 
measured in medium spiny neurons in response to a single 20 ms pulse as well as 
to a 1 s train of pulses at 30 Hz stimulation.  Medium spiny neurons were identified 
by their shape and passive membrane properties (Cm, Rm, and decay constant) 
immediately after break-in in the voltage-clamp configuration holding at -70mV.   
 
Activation of ChR2-expressing fibers was performed by using square 
illumination patterns (as described (Larsen et al., 2014)) in animals previously used 
in the optical ICSS paradigm.  In response to these stimuli, mean IPSC amplitude, 
decay/rise tau, and total charge were measured by averaging ≥6 consecutive traces. 
Optical inhibitory postsynaptic currents (oIPSCs) were measured in ventral striatal 
MSNs which were selected by their membrane properties. oIPSCs were isolated by 
including DNQX (20 µM) and DL-APV (100 µM) in the external solution. Patch 
35 
 
pipette open-tip resistances were between 2.5-6 MΩ and were backfilled with (in 
mM): 125 CsCl, 10 TEA-Cl, 0.1 EGTA (Cs-OH), 10 Hepes, 3.3 QX314, 1.8 MgCl2, 4 
ATP, 0.3 GTP, 8 Na2-Phosphocreatine with pH adjusted to 7.25 with 1M CsOH and 
osmolarity adjusted to ~295 by the addition of sucrose. The high internal chloride 
concentration increased the chloride driving force and allowed for oIPSCs to be 
more easily resolved at -70 mV. Changes in series and input resistance were 
monitored throughout the experiment and did not differ between genotypes (p>0.05). 
Recordings were discarded if series resistance rose above 30 MΩ.   
 
2.5.4 Current-clamp Recordings  
Intrinsic excitability experiments were performed at -50 to -60 mV in ACSF 
containing picrotoxin (50 µM), DNQX (20 µM), and DL-APV (100 µM) to block 
excitatory and inhibitory transmission.  Putative VTA-to-NAc dopaminergic cells were 
selected as described above and pipettes were backfilled with (in mM): 100 K-
gluconate, 20 KCl, 10 Hepes, 0.2 EGTA, 4 ATP, 0.3 GTP, 10 Na2-Phosphocreatine, 
and 0.015 Alexa-488 with pH adjusted to 7.25 with 1M KOH and osmolarity adjusted 
to ~295 by the addition of sucrose.  For frequency-current plots, current was injected 
at 40 pA steps and average AP frequency was calculated to the same current 
injection. Peak amplitude was calculated by averaging the max amplitude for all 
events across all collected traces.  Max instantaneous frequency was calculated by 
taking the inverse of the shortest inter-event interval across all collected traces. 
Changes in series and input resistance were monitored throughout the experiment 
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by giving a test pulse every 30s and measuring the amplitude of the capacitive 
current. Cells were discarded if series resistance rose above 30 MΩ.   
 
2.5.5 Fast-scan Cyclic Voltammetry 
Ventral striatum sections were prepared as described above. Electrochemical 
data were acquired using a custom-written software in LabVIEW (Tar Heel CV) and 
filtered at 1 kHz offline.  Briefly, carbon fiber microelectrodes (50 µM in length) were 
scanned from -0.4 V to 1.3 V at a rate of 400 V/s. Samples were acquired at a rate 
of 10 Hz.   Light pulses (5 ms, 473 nm, 1 mW) were delivered through a 40X 
objective via a high-powered LED (Thorlabs) to evoke dopamine release.  A single 
pulse or 5 light pulses were delivered at 1, 5, 10, 20, 30, and 40 Hz in a randomized 
order.  Immediately after optical stimulation of the slice, background-subtracted 
cyclic voltammograms were generated, which were characteristic of dopamine (peak 
oxidation potential of 600-700 mV). For complete methods please see (Stamatakis 
et al., 2013).   
        
2.5.6 Immunohistochemistry 
Mice were anesthetized with pentobarbital and then perfused with 4% 
paraformaldehyde in PBS (pH ~7.3).  Samples were placed in 10, 20, and then 30% 
sucrose in PBS before being cut at 40 µM using a cryostat (Leica).  Sections were 
collected, rinsed (PBS), and blocked with 5% normal goat serum and 0.2% Triton X-
100 in PBS. Sections were then tumbled in this blocking solution with primary 
antibody for 24 hours at 4°C.  The primary antibodies used in this study were rabbit 
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anti-TH (1:650 Millipore, AB152), chicken anti-EGFP (1:1000 Aves), and mouse anti-
UBE3A (1:750 Sigma clone 3E5, SAB1404508).  Transgenic fluorescent proteins 
expressed via CRE-mediated recombination (Ai9 mice) were not further antibody 
enhanced.  Secondary detection was performed with Alexa Fluor 488, 568, or 633 
conjugated goat anti-rabbit, anti-chicken, or anti-mouse antibodies (Invitrogen).  
Mounted sections were imaged on a Zeiss LSM 710 Confocal Microscope using 
20X/0.8, or 40X/1.3 NA objectives.  Immunohistochemistry was used to validate viral 
injection, fiber placement, and recombination efficiency post-hoc in experimental 
animals.   
 
2.5.7 In vivo optogenetic excitation 
For all behavioral experiments, mice were injected with AAV5-EF1α-DIO-
ChR2-eYFP virus and implanted with bilateral custom-made optical fiber targeted to 
the NAc core (Sparta et al., 2012).  Mice were connected to a ‘dummy’ optical patch 
cable 5 days before the experiment each day for 60 min to habituate them to the 
tether procedure.  Following the tethering procedure, we ran the mice in several 
behavioral procedures (detailed below).  We used a 10 mW, 473 nm laser with a 
stimulation frequency of 30 Hz and a 5 ms pulse width duration for all behavioral 
assays unless otherwise noted.  
 
2.5.8 Real-time Place Preference  
Mice were placed in a behavioral arena (50 x 50 x 25 cm black) for 20 min.  
One side (counterbalanced) of the chamber was paired with optical stimulation.  
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Mice were initially placed in the nonstimulation side at the onset of the experiment 
and were delivered a 5, 10, 20, 30, 40, or 60 Hz (randomized) constant laser 
stimulation each time the mouse crossed to the stimulation side of the chamber until 
the mouse crossed back into the nonstimulation side.  We recorded behavioral data 
via a CCD camera interfaced with Ethovision XT software (Noldus Information 
Technologies).  Mice underwent one session per day during their respective dark 
cycle.   
 
2.5.9 Positive reinforcement procedures and Optical Self-Stimulation 
Behavioral training and testing occurred in mouse operant chambers (Med 
Associates) interfaced with optogenetic stimulation equipment. Behavioral 
paradigms were performed during their respective dark cycle.  Food restricted male 
mice (90% of their free-feeding bodyweight) were trained on a fixed ratio (1:1) 
training schedule for one session per day for 60 min, in which each nose poke 
resulted in 20 µl of a 15% sucrose administration until the number of nose pokes did 
not vary >20% across three consecutive days. In addition, active nose poke ports 
were coupled with a cue light that remained on.  With each successful nose poke, 
the cue light turned off and a tone would be presented for 3 s.  Once the mice 
reached a stable number of nose pokes, they were habituated for 5 consecutive 
days to the patch cable with optical stimulation (3 s of 30 Hz) time-locked to the cue 
following each active nose poke.  After the 5 day habituation phase, mice were then 
tested following a 2 day break.  Active and inactive nose pokes were recorded in 
addition to time-stamps.  
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2.5.10 Statistics and Data Analysis 
We plotted all data and performed all statistical analyses on GraphPad Prism 
software.  All graphs are represented as the mean ± SEM.  For statistical analyses, 
we used two-way ANOVA (Figs. 2.1b2, 2.6a-b2, 2.4a3), one-way ANOVA (Fig. 
2.6a2-b), or two-tailed student’s t-test (Fig. 2.6d2-4, 2.3c2, 2.4a2, and 2.5). Statistical 
significance is represented as follows: *p<0.05, **p<0.02, and ***p<0.001.  Minimum 
sample sizes were estimated from previously published data sets with similar 
experimental parameters. The only data points that were discarded were done so 
before unblinding and only because the data points did not meet a priori criteria for 
data inclusion (e.g. – series resistance in a whole-cell recording was above our 
established limit for inclusion).  No outlier test was used to discount any data point, 
and all data points were included within the summarized graphs.   
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Figure 2.1:  Ube3am–/p+ mice are hyper-motivated to self-stimulate TH-positive 
VTA-to-NAc terminals.  
(a1) Schematic representation of DIO-ChR2-eYFP viral transduction within the 
VTA along with NAc chronic fiber placements into THCRE-positive mice.  (a2) 
Immunohistochemistry of ChR2-eYFP (green), and DAPI (blue) in a THCRE ::Ube3am–
/p+  mouse. Scale bar = 500 µM.  (b1)  Cumulative response plots showing 
cumulative nose pokes that trigger a 30 Hz, 473 nm stimulus (active nose pokes) in 
representative mice. (b2) Average number of nose pokes for triggering (active nose 
pokes) or not triggering (inactive) 30 Hz optical stimulation across a 60 minute 
session.  THCRE::Ube3am–/p+ mice were significantly more motivated to trigger optical 
stimulation than THCRE::Ube3am+/p+ mice (n=7 for each group,*p<0.05). All bars 
represent the mean ± SEM.   
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Figure 2.2:  THCRE-mediated recombination of the maternally inherited 
Ube3aFLOX allele abolishes UBE3A within VTA but not striatal neurons.   
(a1) Schematic of strategy used to generate C57BL/6 mice carrying the 
Ube3aFLOX allele. Note that these mice have been fully anatomically and molecularly 
validated (Judson et al., in review).  (a2) Immunohistochemistry showing UBE3A-
positive (white) and TH-positive (red) neurons in THCRE::Ube3aFLOX/p+ mice.  Scale 
bar = 500µM (top) or 50µM (bottom).  High magnification views are of area outlined 
by white box. Arrowhead represents residual UBE3A expression within a TH-positive 
neuron.  (a3) Quantification demonstrating a recombination efficiency of ~80% (n=2 
mice). (b) Immunohistochemistry showing ChR2-eYFP (green), UBE3A (white), and 
DAPI (blue) in the striatum of THCRE::Ube3aFLOX/p+ mice following injection of DIO-
ChR2-eYFP into the VTA.  UBE3A expression is qualitatively similar to wild-type 
levels of UBE3A within the striatum. ac=anterior commissure. 
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Figure 2.3:  THCRE::Ube3am–/p+ mice exhibit greater preference for stimulation 
of TH-positive VTA-to-NAc terminals than wild-type mice but learn on similar 
timescales.  
(a) Wire frame and heat plots representing a single mouse’s movements in 
real-time place preference arena during a 20 min session.  (a2-4) Average data 
showing % time THCRE::Ube3am–/p+, THCRE::Ube3am+/p+, and THCRE negative control  
mice spent in side triggering optical stimulation at 20, 30, or 40 Hz (p’s<0.05). (b) 
Mean velocity in THCRE::Ube3am–/p+, THCRE::Ube3am+/p+, and THCRE negative controls 
(n=5/genotype). (c1) Plot showing active nose pokes for each mouse across sucrose 
training days.  (c2) Average number of nose pokes performed on the last sucrose 
training day for THCRE::Ai9::Ube3am–/p+  and THCRE::Ai9::Ube3am+/p+ mice (p=0.84).  
Bars represent mean ± SEM. 
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Figure 2.4: Optically evoked dopamine release is similar in TH-positive VTA-to-
NAc terminals in Ube3am–/p+ and Ube3am+/p+ mice.  
(a1) Representative fast-scan voltammetric recordings from ventral striatal 
slices in both THCRE::Ube3am–/p+ and THCRE::Ube3am+/p+ mice. Insets represent 
background subtracted electrochemical signal characteristic of oxidized dopamine.  
Right: Consecutive background subtracted voltammogram recorded over an 8-s 
interval.  Applied electrode potential (Eapps vs. Ag/AgCl reference electrode) is shown 
versus time. (a2) Light-evoked current is similar in both genotypes at 1-pulse 
(p=0.99, n=8, 9) and (a3) across a range of frequencies (p= 0.83, n=11, 12). 
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Figure 2.5:  Maternal deletion of Ube3a in TH-positive neurons has no apparent 
effect on intrinsic excitability and inhibitory input onto VTA neurons.  
(a) Representative traces and average data showing action potential firing 
rates to increasing current injections in Ai9-positive VTA neurons in 
THCRE::Ai9::Ube3am–/p+  and THCRE::Ai9::Ube3am+/p+ mice (n=18/ group, p=0.70).  (b)  
Average values of resting membrane potential (p=0.46), membrane resistance 
(p=0.25), maximum instantaneous firing frequency (p=0.22), and average action 
potential (AP) peak amplitude (p=0.32) of Ai9-positive neurons.  (c) Representative 
traces and average data showing spontaneous inhibitory postsynaptic currents 
(sIPSCs) in Ai9-positive neurons (n=12 for each genotype, p=0.42, p=0.24). 
GABAergic currents were validated by bath application of SR95531.  All bars 
represent mean ± SEM. 
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Figure 2.6:  Deleting Ube3a in TH-positive neurons decreases GABA co-
release and is sufficient to enhance motivational behavior.   
(a) Average nose pokes for inactive and active ports triggering 30 Hz optical 
intracranial self-stimulation in a 60 minute behavioral session (n=5 and 7, *p<0.02).  
Experimental design was similar to that schematized in Figure 1a1, except that 
THCRE::Ube3aFLOX/p+ and THCRE::Ube3am+/p+ mice were examined to selectively 
delete Ube3a and optically stimulate TH+ VTA-to-NAc terminals.  (b1) Representative 
fast-scan cyclic voltammograms assessing dopamine release within the ventral 
striatum of THCRE::Ube3aFLOX/p+ and THCRE::Ube3am+/p+ mice.  Dopamine release 
was evoked by 30 Hz (5-pulses) optical stimulation. Insets represent background 
subtracted electrochemical signal characteristic of oxidized dopamine. (b2) Averaged 
optically-evoked dopamine release at a range of frequencies demonstrates that 
there are no statistical differences between genotypes (n=6 and 7, p>0.05). (c) 
Schematic representing protocol for whole-cell optical IPSC (oIPSC) recordings 
within the NAc of THCRE::Ube3aFLOX/p+ mice.  IPSCs were pharmacologically isolated 
(see Methods).  (d1) Representative oIPSC traces measured in THCRE::Ube3aFLOX/p+ 
and THCRE::Ube3am+/p+ mice and evoked by single pulses (20ms) or 30 Hz trains of 
stimulation. The pharmacological isolation of GABAergic currents was validated by 
application of the antagonist SR95531. (d2) Average peak amplitude of single 
oIPSCs demonstrate a significant reduction of GABAergic currents in Ube3aFLOX/p+ 
mice (n=13 and 15, **p<0.05).  (d3) Average decay kinetics of oIPSCs analyzed in 
panel d2 (p=0.61). Representative traces are shown with normalized amplitude to 
demonstrate similar current decay kinetics. (d4) Average oIPSC charge evoked 
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using a similar 30 Hz optical stimulation paradigm employed behaviorally (see panel 
“a”) and tested in vitro (bottom traces of “d1”).  THCRE::Ube3aFLOX/p+ animals showed 
a significant decrease in GABA co-release (n=10 and 14,**p<0.05). All bars 
represent the mean ± SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
 
 
CHAPTER 3 
 
 
POTENTIAL MECHANISMS UNDERLYING HYPERMOTIVATION IN CELL TYPE-
SPECIFIC LOSS OF UBE3A 
 
 
 The following chapter is subdivided into three sections to provide a 
comprehensive overview of experimental topics that were expanded upon as future 
directions informed by the data presented in Chapter 2.  These subdivisions are 
organized as follows: (i) striatal mechanisms in AS model mice that may contribute 
to synaptic dysregulation, (ii) mechanisms of GABA co-release that may mediate 
motivational drive, and (iii) differing mechanisms of glutamate co-release that are 
unaffected with the loss of Ube3a.   
 
3.1 Striatal mechanisms in AS model mice that may contribute to 
synaptic dysregulation 
Ube3am–/p+ mice have been shown to be less affected by D2 antagonism 
mediated by raclopride administration (Riday et al., 2012) suggesting a potential 
mechanism underlying reward circuitry deficits.  Raclopride similarly affects BSR 
threshold between AS and WT mice but lowers maximum response rate in AS model 
mice suggesting decreased D2-receptor function.  While D2-receptor dysregulation 
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is a candidate within AS model mice, they respond to the same degree to 
D1-receptor antagonism as WT mice (Riday et al., 2012).  D2-receptors are a 
Gi/o-coupled inhibitory auto-receptor that is associated with activation of the indirect 
pathway and acts to inhibit dopaminergic neuron excitability and attenuates DA 
release (Section 1.2.3; (Ford et al., 2006)).  Given that D1- and D2-receptors are 
located both pre- and post-synaptically, the hyper-motivation phenotype observed 
within Ube3aFLOX/p+ mice could potentially arise from a similar mechanism as 
suggested in the AS model mice.  Using a real-time place preference (RTPP) 
paradigm, we coupled i.p. administration of raclopride along with optogenetic 
stimulation in THCRE::Ube3aFLOX/p+ to determine if D2-receptors are similarly affected 
and in AS model mice when Ube3a is eliminated pre-synaptically in TH-expressing 
VTA neurons. Using 30 Hz stimulation, there was a trend for a decrease in 
sensitivity to D2-antagonism mediated by raclopride in THCRE::Ube3aFLOX/p+ 
suggesting that Ube3a may regulate D2-receptor expression levels pre-synaptically 
that could lead to the observed hypermotivation (Fig. 3.1, p=0.059). However, this is 
unlikely given that engineered mice that are deficient for D2-receptors exhibit an 
increase in BSR threshold whereas AS model mice exhibit a decrease in threshold 
for BSR and for optogenetic VTA-to-NAc stimulation (Elmer et al., 2005; Riday et al., 
2012).  In addition, deletion of Ube3a within TH-expressing VTA neurons leads to no 
change in DA release providing further evidence that the mechanism underlying 
enhanced reward-seeking is not directly mediated by D2-receptor dysregulation.  
Moreover, D2-receptor protein expression is similar in AS model mice compared to 
wildtype mice suggesting that the insensitivity to D2 antagonism is not mediated by a 
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change in total D2 expression but rather D2-receptor function (data not shown).    
However, these data do provide some insight into where Ube3a expression is 
required (TH+ neurons in the VTA) and how Ube3a may affect pre-synaptic 
transmission (GABA co-release deficient).  
 
 
3.2 Mechanisms of GABA co-release and mechanisms that may mediate 
motivational drive 
 Dale’s principle states that a neuron can only release one type of 
neurotransmitter regardless of its efferent projections.  However, it has recently been 
identified that neurons are capable of releasing several types of neurotransmitters 
and neuropeptides.   Specifically, mesolimbic dopaminergic neurons are capable of 
releasing glutamate, GABA, and dopamine in concert (Adrover et al., 2014; Hnasko 
and Edwards, 2012; Stuber et al., 2010; Tritsch et al., 2012; Tritsch et al., 2014).  In 
2012, it was first identified that dopaminergic neurons within the SNc can co-release 
GABA within the dorsal striatum (Tritsch et al., 2012).  The mechanism underlying 
this co-release was mediated by GABA vesicular loading through the vesicular 
monoamine transporter (VMAT2) and is independent of VGAT.  This finding was 
further expanded upon in 2014 with the establishment that GABA and DA co-release 
also occurs in dopaminergic neurons projecting to the ventral striatum (Tritsch et al., 
2014).  The mechanisms underlying this phenomenon largely remain unclear but it 
has been revealed that these dopaminergic neurons release GABA in a 
non-canonical manner mediated by VMAT2.  DAergic terminals uptake ambient 
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GABA via membrane transporters GAT1 and VMAT2 and do not express any GABA 
synthetic enzymes (GAD65 and GAD67) contrary to previous reports suggesting that 
approximately 10% of VTA dopaminergic neurons express GAD65 (Tritsch et al., 
2014).  Because of this mechanism, repeated stimulation of these terminals in quick 
succession leads to oIPSC rundown which is an attribute of these synapses that 
needs to be taken under consideration with experimental design.  
 These known mechanisms lead to the hypothesis, along with the deficient 
GABA co-release observed upon Ube3a deletion in TH+ neurons, that perhaps 
Ube3a is required for proper GABA uptake.  To test this hypothesis, we utilized a 
CRE-dependent viral approach in which we exogenously introduced VGAT within 
the same neurons that are deficient for Ube3a.  This will test if exogenous VGAT 
expression is sufficient to (1) rescue enhanced reward-seeking and (2) normalize 
GABA co-release physiologically.  With this approach, we injected 500 nL of a 1:1 
ratio of DIO-ChR2-EYFP along with DIO-VGAT in THCRE::Ube3aFLOX/+ and 
THCRE::Ube3am+/p+ bilaterally within the VTA.  Chronic optical fibers were implanted 
within the NAc as described in section 2.5.1 to specifically target those terminals 
during a behavioral task.  Animals then performed the optical ICSS behavioral task 
at a FR1 reinforcement schedule that delivered 30 Hz optical stimulation.  
Exogenous expression of VGAT within THCRE::Ube3aFLOX/+::DIO-VGAT animals was 
found to be sufficient to rescue the hyper-motivational phenotype previously 
observed (Fig. 3.2a).  While the rescue of motivational drive provided correlative 
evidence that enhancing GABA co-release within VTA terminals was sufficient, it 
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remained unclear if these terminals were then physiologically capable of reinstating 
concomitant GABA transmission as THCRE::Ube3am+/p+::DIO-VGAT. 
 To test this hypothesis, we interrogated this system to ask if GABA co-release 
within THCRE::Ube3aFLOX/+::DIO-VGAT elevated to wild-type levels using in vitro whole-
cell electrophysiology.  Using an optical stimulation paradigm of 1-pulse and 30 Hz, 
there was not a statistical difference in GABA co-release between the two genotypes 
suggesting that extracellular available GABA concentration between Ube3am+/p+ and 
Ube3aFLOX/p+ are similar but that THCRE::Ube3aFLOX/p+ mice exhibit deficient GABA 
uptake (Fig. 3.2b).  These data provide novel correlative evidence for the 
involvement of GABA co-release from dopaminergic terminals in reward-seeking 
behavior.  Currently, we are limited by the technology available to test the behavioral 
consequence of GABA co-release. An interesting future direction to test a true 
causal relationship within a wild-type mouse would be to delete mGAT1 in a cell 
type-specific manner within DAergic neurons in the VTA and test if this leads to an 
increase in motivation.   
 
3.3 Glutamate co-release is unaffected with cell type-specific deletion of 
Ube3a.  
 As mentioned in section 3.2, dopaminergic terminals are capable or releasing 
glutamate, GABA, and dopamine simultaneously.   The mechanisms underlying 
these release events are beginning to come to light and are known to occur in two 
very distinct manners.  GABA and DA are evidenced to be present within the same 
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synaptic vesicles and are uploaded by VMAT2 (Tritsch et al., 2012; Tritsch et al., 
2014).  GABA synthase is not present within DAergic neurons, but GABA is acquired 
from the synaptic cleft and is actively transported via GAT1 (Tritsch et al., 2014).  
However, recently the Morales group has shown that glutamate is not co-released in 
the same manner as GABA (Zhang et al., 2015) but occur in separate microdomains 
within the same terminal. Furthermore, the mechanism underlying vesicular loading 
of glutamate is mediated by VLGUT2 and not VMAT2 as suggested for GABA co-
release (Tritsch et al., 2012; Zhang et al., 2015).  To test if glutamate co-release is 
affected upon THCRE specific deletion of Ube3a, we injected DIO-ChR2-EYFP into 
THCRE::Ube3am+/p+ and THCRE::Ube3aFLOX/p+  mice and used a 1-pulse optical 
stimulation paradigm as described in section 3.2. We blocked all inhibitory synaptic 
transmission by placing picrotoxin (50 µM) in the recording solution to 
pharmacologically isolate excitatory events.  We saw no statistically significant 
change in glutamate co-release between THCRE::Ube3am+/p+ and 
THCRE::Ube3aFLOX/p+  mice suggesting that GABA co-release is uniquely affected by 
the loss of Ube3a (Fig. 3.3) and that VGLUT2-mediated synaptic vesicle loading is 
also unaffected.   
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3.5 Materials and Methods 
 
3.5.1 Experimental Subjects and Stereotaxic Surgeries 
Cg-Tg-TH:Cre mice (008601) were obtained through Jackson Laboratories. 
Ube3a-floxed mice were engineered by Matthew Judson in conjunction with the 
UNC Animal Models Core.  These mice were on a C57/BL6 background except for 
the Ube3a-floxed mice which were mixed with a 129S6:C57BL/6 background but 
backcrossed eight generations before experimental use. Mice for 
electrophysiological recordings were aged P60-P90 and were compared to wild-type 
age and sex matched controls.  The experimenter was blind to genotype and 
littermate controls were used when possible.  Behavioral mice were group housed 
until surgery and were taken at 25-30g.  We anesthetized the mice with ketamine 
(150mg/kg) and xylazine (50mg/kg) and placed the mice in a stereotaxic frame (Kopf 
Instruments).  We bilaterally microinjected 0.5µL of purified adeno-associated virus 
(~1012 infections units per ml, packaged and tittered by the UNC Viral Vector Core 
Facility) into the VTA (coordinates from bregma: -3.15 anterior/posterior, ±0.75 
medial/lateral, -4.75 dorsal/ventral). VTA neurons in THCre positive Ube3am-/p+, 
Ube3aFLOX/+, or Ube3am+/p+ mice were trasnsduced with virus encoding ChR2-eYFP 
under the control of the human synapsin (SYN1) promoter along with VGAT 
(generously provided by Bernardo Sabatini).  Following surgery, mice were 
individually housed.  For behavioral experiments, we also implanted mice with 
bilateral chronic fiber directed above the NAc (coordinates from bregma: +1.2 A/P, 
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±1.6 M/L, -4.6 D/V at a 10°angle). We performed all experiments 5-8 weeks after 
surgery.  We conducted all procedures in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the National Institutes of Health, and 
with approval of the UNC Institutional Animal Care and Use committees.   
 
3.5.2 In vivo optogenetic excitation 
For all behavioral experiments, mice were injected with AAV5-EF1α-DIO-
ChR2-eYFP virus and implanted with bilateral custom-made optical fiber targeted to 
the NAc core (Sparta et al., 2012).  Mice were connected to a ‘dummy’ optical patch 
cable 5 days before the experiment each day for 60 min to habituate them to the 
tether procedure.  Following the tethering procedure, we ran the mice in several 
behavioral procedures (detailed below).  We used a 10 mW, 473 nm laser with a 
stimulation frequency of 30 Hz and a 5 ms pulse width duration for all behavioral 
assays unless otherwise noted.  
 
3.5.3 Real-time Place Preference  
We placed mice in a behavioral arena (50 x 50 x 25 cm black) for 20 min.  
One (counterbalanced) side of the camber was assigned as the stimulation side.  
The mouse was placed in the nonstimulated side at the onset of the experiment and 
delivered a 5, 10, 20, 30, 40, or 60 Hz (randomized) constant laser stimulation each 
time the mouse crossed to the stimulation side of the chamber until the mouse 
crossed back into the nonstimulation side.  We recorded behavioral data via a CCD 
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camera interfaced with Ethovision XT software (Noldus Information Technologies).  
Mice underwent one session per day.   
In vivo pharmacology:  After mice completed the RTPP task, they were 
administered i.p. with raclopride (0.1 mg/kg), SCH23390 (0.06 mg/kg), or saline 
(counterbalanced between days).  All drugs were dissolved in 0.9% sterile saline. 
Mice were allowed to recover post-injection for 20 min in their home cage.  Following 
recovery, mice were run through the RTPP task as described above except received 
a single frequency (30 Hz) stimulation.  Mice had at least 24 hours without 
manipulation between each i.p. drug administration.    
 
3.5.4 Voltage-clamp Recordings 
In vitro optogenetic stimulation of GABA co-release was performed in the 
same manner as stated in section 2.5.3. Briefly, 250 µM coronally prepared striatal 
sections were placed in a bath containing AMPA and NMDA receptor blockers or 
picrotoxin then stimulated with either 1, 20 ms optical pulse or a 1 s train at 30 Hz.   
 
3.5.5 Positive reinforcement procedures and Optical Self-Stimulation 
Behavioral training and testing occurred in mouse operant chambers (Med 
Associates) interfaced with optogenetic stimulation equipment. Behavioral 
paradigms were performed during their respective dark cycle.  Food restricted male 
mice (90% of their free-feeding bodyweight) were trained on a fixed ratio (1:1) 
training schedule for one session per day for 60 min, in which each nose poke 
resulted in 20 µl of a 15% sucrose administration until the number of nose pokes did 
61 
 
not vary >20% across three consecutive days. In addition, active nose poke ports 
were coupled with a cue light that remained on.  With each successful nose poke, 
the cue light turned off and a tone would be presented for 3 s.  Once the mice 
reached a stable number of nose pokes, they were habituated for 5 consecutive 
days to the patch cable with optical stimulation (3 s of 30 Hz) time-locked to the cue 
following each active nose poke.  After the 5 day habituation phase, mice were then 
tested following a 2 day break.  Active and inactive nose pokes were recorded in 
addition to time-stamps. 
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Figure 3.1: Cell type-specific deletion of Ube3a in TH+ neurons may lead to 
insensitivity to D2-antagonism.  
        Mice were placed in a real-time place-preference arena after being injected with 
raclopride (0.1 mg/kg) 20 min prior to behavioral testing. Mean velocity was then 
measured across an entire 20 minute session.  While there is no statistically significant 
difference (p=0.59), there is a trend suggesting that THCRE::Ube3aFLOX/p+ mice may be 
insensitive to D2 antagonism mediated by raclopride that should be investigated 
further (n=8 and 6).  Bars represent mean ± SEM.   
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Figure 3.2: Exogenous expression of VGAT in TH+ cells ameliorates enhanced 
reward-seeking and normalizes GABA co-release in THCRE::Ube3aFLOX/p+ mice.                                     
        (a) Left:  Cumulative response plots showing cumulative nose pokes that trigger 
a 30 Hz, 473 nm stimulus (active nose pokes) in representative mice. Right: Average 
number of nose pokes for triggering (active nose pokes) or not triggering (inactive) 
30 Hz optical stimulation across a 60 minute session.  THCRE::Ube3am+/p+::DIO-VGAT 
and THCRE::Ube3aFLOX/p+::DIO-VGAT mice poked at similar levels for self-stimulation in 
the presence of VGAT expression (n=5, 4; p=0.06).  (b) Left: Representative oIPSC 
traces measured in THCRE::Ube3aFLOX/p+::DIO-VGAT and THCRE::Ube3am+/p+::DIO-VGAT 
mice and evoked by single pulses (20 ms) or 30 Hz trains of stimulation. The 
pharmacological isolation of GABAergic currents was validated by application of the 
antagonist SR95531. Center: Average peak amplitude of single oIPSCs demonstrate 
similar GABAergic currents in Ube3aFLOX/p+::DIO-VGAT mice when compared to controls 
(n=10 and 7, p=0.689).  Right:  Average oIPSC charge evoked using a similar 30 Hz 
optical stimulation paradigm employed behaviorally and tested in vitro (n= 7 and 7, 
p=0.589).  Bars represent mean ± SEM.  
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Figure 3.3: Glutamate co-release is similar between THCRE::Ube3am+/p+ and 
THCRE::Ube3aFLOX/p+ mice. (a) Representative averaged traces (≥ 6 sweeps) of 
glutamate co-release from TH-expressing VTA-to-NAc terminals.  (b) Average peak 
amplitude of single oEPSCs demonstrate similar excitatory currents in 
THCRE::Ube3am+/p+ and THCRE::Ube3aFLOX/p+ mice (n=13/genotype, p=0.59). All bars 
represent mean ± SEM.  
 
 
 
 
66 
 
 
 
 
CHAPTER 4 
 
DISCUSSION 
 
 
 The following chapter is subdivided into two main sections that are composed 
of avenues that could be pursued guided by the data presented in chapters 2 and 3.  
The first subdivision discusses (ii) upstream pathways that could contribute to circuit 
dysfunction, and the second discusses (ii) molecular constituents in AS model mice 
that may contribute to disrupted GABA co-release which may be potential neuronal 
substrates of UBE3A. 
 
 
4.1 Upstream pathways that could contribute to circuit dysfunction 
As described in section 1.2.3, there are several additional anatomical targets 
upstream of the VTA that are essential to appetitive behaviors such as the dorsal 
striatum and mPFC. Mice develop a strong preference for optical stimulation of the 
VTA-to-NAc pathway that may be exclusively regulated exclusively by GABA co-
release.  However, this does not take into account mPFC and dorsal striatum 
mediated higher order processes also play an important regulatory role in motivation 
and reward-seeking.  An additional aspect to consider is that these mPFC and 
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striatal targets reciprocally target the VTA providing bidirectional feedback to the 
VTA (Kauer and Malenka, 2007). DA release from the VTA during a rewarding 
stimulus results in post-synaptic neurons expressing a form of NMDAR-dependent 
LTP that increases AMPA/NMDA ratio (Kauer and Malenka, 2007) in order to make 
an association more salient.  Because of these additional VTA targets and their 
reciprocal connections, an interesting future direction would be to assess the 
plasticity induced within the striatum in THCRE::Ube3aFLOX/p+ and THCRE::Ube3am+/p+ 
mice and how they may differ after optical self-stimulation.  In addition, it will be 
necessary to interrogate several parts of the circuit and assay if VTA-to-striatum-to-
mPFC connections mediate the same hyper-motivational phenotypes as VTA-to-
NAc as well as VTA-to-dorsal striatum.  
In addition, the mPFC has been highlighted for its important role in behavioral 
extinction during extinction of reward-seeking and fear-conditioning (Kim et al., 2009; 
Milad and Quirk, 2002; Sparta et al., 2014).  Recently, in vivo optogenetic 
manipulations of parvalbumin-containing fast spiking interneurons (PV+ FSIs) has 
shown that activation of PV+ FSI accelerates extinction of a reward-seeking 
paradigm (Sparta et al., 2014).  Given that AS model mice are known to have 
deficits in inhibitory transmission (Wallace et al., 2012) and GABA co-release from 
TH+ neurons (Chapter 2), an intriguing future direction would be to test extinction of 
a reward-seeking paradigm in AS model mice. If there are differences, testing if this 
change coincides with aberrant inhibitory drive in the PFC would be of interest.   
The Philpot lab has acquired preliminary, unpublished data suggesting that 
instrumental extinction is enhanced in AS model mice as in Fmr1 knockout mice 
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(Sidorov et al., 2014). Considering the robust role the mPFC has in working memory 
(Seamans and Yang, 2004), which facilitates the acquisition of reinforcing behaviors, 
the mPFC will be an important anatomical target to study in THCRE::Ube3aFLOX/p+ 
mice.  The mPFC receives dopaminergic input from the VTA (Kauer and Malenka, 
2007), and in conjunction with the behavioral extinction data, provides an anatomical 
substrate to consider in AS circuitry.  An interesting electrophysiological property to 
test would be if the dopaminergic inputs to the mPFC also co-release GABA and if 
so, if this is altered in THCRE::Ube3aFLOX/p+ mice.  In addition, PV+ FSIs have an 
important role in modulating extinction. The use of genetic tools (PV-specific CRE) 
would be necessary to test using selective Ube3a deletion in PV+ interneurons.  As 
mentioned above, the use optogenetics has elucidated an important role for FSI in 
extinction. The characterized excitatory-inhibitory imbalance within AS model mice 
would suggest a hyperexcitability due to a decrease in inhibition (Wallace et al., 
2012).  Because AS mice are thought to have enhanced instrumental extinction, an 
interesting future direction would be to delete Ube3a in PV+ FSI and test if the loss of 
Ube3a specifically within these neurons alters instrumental extinction.     
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4.2 Molecular constituents in AS model mice that may contribute to 
 disrupted GABA co-release 
 GAT1 has been proposed as a potential UBE3A substrate within cerebellar 
granule cells (Egawa et al., 2012).  Loss of UBE3A results in an increase in GAT1 
expression which depletes available ambient GABA in the extra-synaptic cleft 
leading to a decrease in tonic inhibition.  Further evidence for GAT1 as a molecular 
substrate lies in biochemical evidence analyzing cerebellar protein lysates from both 
Ube3am–/p+ and Ube3am+/p+ mice that suggests loss of Ube3a results in increased 
GAT1 expression (Egawa et al., 2012).  These results provide convincing evidence 
for GAT1 as a potential neuronal substrate for UBE3A and is suggestive of 
hyper-functional GABA reuptake.   Within UBE3A-null VTA terminals, this seems like 
an unlikely mechanism for the observed decrease in GABA co-release.  If GAT1 
were upregulated within VTA-to-NAc terminals, this would suggest a possible 
increase in GABA co-release that would theoretically be at a ceiling that would not 
be affected by VGAT expression.  Considering that the exogenous viral expression 
of VGAT within TH+ terminals leads to an increase in GABA co-release and, a 
rescue in reward-seeking behavior, it is unlikely that GAT1 is hyper-functional within 
this anatomical region within UBE3A-deficient neurons.  However, GAT1 would 
mediate GABA reuptake and is not directly related to vesicular loading of GABA.  
There is a possibility that UBE3A may have a role in regulating GABA vesicular 
loading within these terminals leading to dysfunctional concomitant GABA release in 
dopaminergic terminals.  While this is a probable hypothesis, cortical VGAT 
expression within Ube3a-deficient mice is similar to wild-type mice (Wallace et al., 
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2012) but there is a marked increase in clathrin coated vesicles that suggests 
defective vesicle recycling.  While it is not clear how the loss of Ube3a leads to a 
decrease in inhibitory transmission, candidates that should be considered for future 
studies include VGAT, VMAT2, and GAT1 in addition to vesicular docking proteins 
like synaptojanin or endophilin in VTA terminals (Cremona et al., 1999; Milosevic et 
al., 2011; Wallace et al., 2012). 
 More convincingly, GAT1 and GAT4 are the two GABA transporters that have 
been shown to be the source of GABA uptake for DAergic terminals in the VTA 
(Tritsch et al., 2014).  Tritsch and colleagues have shown that VTA DAergic neurons 
do not express GABA synthase (Gad65/67) but, actively use GAT1/4 to uptake 
GABA from the extrasynaptic cleft.  The data presented in chapters 2 and 3, along 
with the proposal of GAT1 as a UBE3A substrate, provide convincing evidence that 
UBE3A may, in fact, regulate GAT1 function leading to dysfunctional GABA 
co-release (Fig. 4.1).  Given this possibility, a future direction of interest would be to 
perform a combinatorial approach of cell type-specific labeling in 
THCRE::Ube3aFLOX/p+ mice along with ultrastructual imaging (e.g. electron 
microscopy) to determine if GAT1 expression is changed upon loss of Ube3a.  In 
addition, we have shown that cell type-specific exogenous expression can 
ameliorate the hypermotivational phenotype observed in THCRE::Ube3aFLOX/p+ mice. 
Therefore, it would be constructive to test if exogenous expression of GAT1 within 
these same neurons can rescue hypermotivation and GABA co-release upon Ube3a 
deletion in TH+ neurons or if cell type-specific deletion of GAT1 within TH+ neurons in 
wildtype mice phenocopy THCRE::Ube3aFLOX/p+ mice.          
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Figure 4.1: A proposed synaptic model within the nucleus accumbens.  
 A dopaminergic terminal (green) and medium spiny neuron terminal (red) are 
represented along with the key components that have been informed by the data 
presented in this thesis. A synaptic vesicle is shown that contains three different 
neurotransmitters dopamine, glutamate and GABA that are being released by the 
optically driven ChR2 leading to action potential generation.  VMAT fluxes in these 
neurotransmitters into the synaptic vesicle to package them for future membrane 
docking and release. GAT1 is a membrane bound transporter that imports GABA 
into a dopaminergic terminal and is illustrated as a bidirectional process by the 
arrows.  UBE3A is represented as possibly being associated with GAT1 as a 
proposed substrate to facilitate GABA influx.  Loss of UBE3A may lead to 
attentuated GABA influx leading to the decrease of GABA co-release observed in 
THCRE::UBE3AFLOX/p+ mice. Action potentials represented in the DAergic terminal are 
optogenetically driven to specifically drive these terminals to gain the ability to 
observe these co-release phenomenon in the post-synaptic MSN.  
 
 
 
 
 
 
 
73 
 
 
REFERENCES 
 
Adrover, M.F., Shin, J.H., and Alvarez, V.A. (2014). Glutamate and dopamine 
transmission from midbrain dopamine neurons share similar release properties but 
are differentially affected by cocaine. J Neurosci 34, 3183-3192. 
Angelman, H. (1965). Puppet Children - a Report on 3 Cases. Dev Med Child Neurol 
7, 681-&. 
Bjorklund, A., and Dunnett, S.B. (2007). Dopamine neuron systems in the brain: an 
update. Trends Neurosci 30, 194-202. 
Bromberg-Martin, E.S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in 
motivational control: rewarding, aversive, and alerting. Neuron 68, 815-834. 
Clayton-Smith, J. (2003). Genomic imprinting as a cause of disease. BMJ 327, 
1121-1122. 
Cooper, E.M., Hudson, A.W., Amos, J., Wagstaff, J., and Howley, P.M. (2004). 
Biochemical analysis of Angelman syndrome-associated mutations in the E3 
ubiquitin ligase E6-associated protein. J Biol Chem 279, 41208-41217. 
Cremona, O., Di Paolo, G., Wenk, M.R., Luthi, A., Kim, W.T., Takei, K., Daniell, L., 
Nemoto, Y., Shears, S.B., Flavell, R.A., et al. (1999). Essential role of 
phosphoinositide metabolism in synaptic vesicle recycling. Cell 99, 179-188. 
Dichter, G.S., Damiano, C.A., and Allen, J.A. (2012). Reward circuitry dysfunction in 
psychiatric and neurodevelopmental disorders and genetic syndromes: animal 
models and clinical findings. J Neurodev Disord 4, 19. 
Dindot, S.V., Antalffy, B.A., Bhattacharjee, M.B., and Beaudet, A.L. (2008). The 
Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and 
maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 
17, 111-118. 
Dolen, G., Darvishzadeh, A., Huang, K.W., and Malenka, R.C. (2013). Social reward 
requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 
501, 179-184. 
Dreyer, J.K., Herrik, K.F., Berg, R.W., and Hounsgaard, J.D. (2010). Influence of 
phasic and tonic dopamine release on receptor activation. J Neurosci 30, 14273-
14283. 
Egawa, K., Kitagawa, K., Inoue, K., Takayama, M., Takayama, C., Saitoh, S., 
Kishino, T., Kitagawa, M., and Fukuda, A. (2012). Decreased tonic inhibition in 
74 
 
cerebellar granule cells causes motor dysfunction in a mouse model of Angelman 
syndrome. Sci Transl Med 4, 163ra157. 
Elmer, G.I., Pieper, J.O., Levy, J., Rubinstein, M., Low, M.J., Grandy, D.K., and 
Wise, R.A. (2005). Brain stimulation and morphine reward deficits in dopamine D2 
receptor-deficient mice. Psychopharmacology (Berl) 182, 33-44. 
Farook, M.F., DeCuypere, M., Hyland, K., Takumi, T., LeDoux, M.S., and Reiter, L.T. 
(2012). Altered serotonin, dopamine and norepinepherine levels in 15q duplication 
and Angelman syndrome mouse models. PLoS One 7, e43030. 
Ferdousy, F., Bodeen, W., Summers, K., Doherty, O., Wright, O., Elsisi, N., Hilliard, 
G., O'Donnell, J.M., and Reiter, L.T. (2011). Drosophila Ube3a regulates monoamine 
synthesis by increasing GTP cyclohydrolase I activity via a non-ubiquitin ligase 
mechanism. Neurobiol Dis 41, 669-677. 
Fields, H.L., and Margolis, E.B. (2015). Understanding opioid reward. Trends 
Neurosci 38, 217-225. 
Floresco, S.B. (2015). The nucleus accumbens: an interface between cognition, 
emotion, and action. Annu Rev Psychol 66, 25-52. 
Ford, C.P., Mark, G.P., and Williams, J.T. (2006). Properties and opioid inhibition of 
mesolimbic dopamine neurons vary according to target location. J Neurosci 26, 
2788-2797. 
Frank, M.J. (2005). Dynamic dopamine modulation in the basal ganglia: a 
neurocomputational account of cognitive deficits in medicated and nonmedicated 
Parkinsonism. J Cogn Neurosci 17, 51-72. 
Gantz, S.C., Ford, C.P., Neve, K.A., and Williams, J.T. (2011). Loss of Mecp2 in 
substantia nigra dopamine neurons compromises the nigrostriatal pathway. J 
Neurosci 31, 12629-12637. 
Geschwind, D.H., and Levitt, P. (2007). Autism spectrum disorders: developmental 
disconnection syndromes. Curr Opin Neurobiol 17, 103-111. 
Grace, A.A. (1991). Regulation of spontaneous activity and oscillatory spike firing in 
rat midbrain dopamine neurons recorded in vitro. Synapse 7, 221-234. 
Grace, A.A., Floresco, S.B., Goto, Y., and Lodge, D.J. (2007). Regulation of firing of 
dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30, 
220-227. 
Grace, A.A., and Onn, S.P. (1989). Morphology and electrophysiological properties 
of immunocytochemically identified rat dopamine neurons recorded in vitro. J 
Neurosci 9, 3463-3481. 
75 
 
Hamilton, P.J., Campbell, N.G., Sharma, S., Erreger, K., Herborg Hansen, F., 
Saunders, C., Belovich, A.N., Consortium, N.A.A.S., Sahai, M.A., Cook, E.H., et al. 
(2013). De novo mutation in the dopamine transporter gene associates dopamine 
dysfunction with autism spectrum disorder. Mol Psychiatry 18, 1315-1323. 
Harbord, M. (2001). Levodopa responsive Parkinsonism in adults with Angelman 
Syndrome. J Clin Neurosci 8, 421-422. 
Hnasko, T.S., and Edwards, R.H. (2012). Neurotransmitter corelease: mechanism 
and physiological role. Annu Rev Physiol 74, 225-243. 
Huang, H.S., Burns, A.J., Nonneman, R.J., Baker, L.K., Riddick, N.V., Nikolova, 
V.D., Riday, T.T., Yashiro, K., Philpot, B.D., and Moy, S.S. (2013). Behavioral 
deficits in an Angelman syndrome model: effects of genetic background and age. 
Behav Brain Res 243, 79-90. 
Huys, Q.J., Daw, N.D., and Dayan, P. (2015). Depression: A Decision-Theoretic 
Analysis. Annu Rev Neurosci 38, 1-23. 
Jiang, Y.H., Armstrong, D., Albrecht, U., Atkins, C.M., Noebels, J.L., Eichele, G., 
Sweatt, J.D., and Beaudet, A.L. (1998). Mutation of the Angelman ubiquitin ligase in 
mice causes increased cytoplasmic p53 and deficits of contextual learning and long-
term potentiation. Neuron 21, 799-811. 
Jones, S.R., O'Dell, S.J., Marshall, J.F., and Wightman, R.M. (1996). Functional and 
anatomical evidence for different dopamine dynamics in the core and shell of the 
nucleus accumbens in slices of rat brain. Synapse 23, 224-231. 
Kaphzan, H., Buffington, S.A., Jung, J.I., Rasband, M.N., and Klann, E. (2011). 
Alterations in intrinsic membrane properties and the axon initial segment in a mouse 
model of Angelman syndrome. J Neurosci 31, 17637-17648. 
Kauer, J.A., and Malenka, R.C. (2007). Synaptic plasticity and addiction. Nat Rev 
Neurosci 8, 844-858. 
Keeler, J.F., Pretsell, D.O., and Robbins, T.W. (2014). Functional implications of 
dopamine D1 vs. D2 receptors: A 'prepare and select' model of the striatal direct vs. 
indirect pathways. Neuroscience 282C, 156-175. 
Kim, J.H., Hamlin, A.S., and Richardson, R. (2009). Fear extinction across 
development: the involvement of the medial prefrontal cortex as assessed by 
temporary inactivation and immunohistochemistry. J Neurosci 29, 10802-10808. 
Lammel, S., Hetzel, A., Hackel, O., Jones, I., Liss, B., and Roeper, J. (2008). Unique 
properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine 
system. Neuron 57, 760-773. 
76 
 
Lammel, S., Ion, D.I., Roeper, J., and Malenka, R.C. (2011). Projection-specific 
modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 
70, 855-862. 
Lammel, S., Lim, B.K., and Malenka, R.C. (2014). Reward and aversion in a 
heterogeneous midbrain dopamine system. Neuropharmacology 76 Pt B, 351-359. 
Lammel, S., Steinberg, E.E., Foldy, C., Wall, N.R., Beier, K., Luo, L., and Malenka, 
R.C. (2015). Diversity of transgenic mouse models for selective targeting of midbrain 
dopamine neurons. Neuron 85, 429-438. 
Landers, M., Calciano, M.A., Colosi, D., Glatt-Deeley, H., Wagstaff, J., and Lalande, 
M. (2005). Maternal disruption of Ube3a leads to increased expression of Ube3a-
ATS in trans. Nucleic Acids Res 33, 3976-3984. 
Larsen, R.S., Smith, I.T., Miriyala, J., Han, J.E., Corlew, R.J., Smith, S.L., and 
Philpot, B.D. (2014). Synapse-specific control of experience-dependent plasticity by 
presynaptic NMDA receptors. Neuron 83, 879-893. 
Laurent, V., and Balleine, B.W. (2015). Factual and Counterfactual Action-Outcome 
Mappings Control Choice between Goal-Directed Actions in Rats. Curr Biol 25, 
1074-1079. 
Mabb, A.M., Judson, M.C., Zylka, M.J., and Philpot, B.D. (2011). Angelman 
syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. 
Trends Neurosci 34, 293-303. 
Margolis, E.B., Lock, H., Hjelmstad, G.O., and Fields, H.L. (2006). The ventral 
tegmental area revisited: is there an electrophysiological marker for dopaminergic 
neurons? J Physiol 577, 907-924. 
Martinez-Noel, G., Galligan, J.T., Sowa, M.E., Arndt, V., Overton, T.M., Harper, 
J.W., and Howley, P.M. (2012). Identification and proteomic analysis of distinct 
UBE3A/E6AP protein complexes. Mol Cell Biol 32, 3095-3106. 
Matsuura, T., Sutcliffe, J.S., Fang, P., Galjaard, R.J., Jiang, Y.H., Benton, C.S., 
Rommens, J.M., and Beaudet, A.L. (1997). De novo truncating mutations in E6-AP 
ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15, 74-77. 
McCarthy, S.E., Makarov, V., Kirov, G., Addington, A.M., McClellan, J., Yoon, S., 
Perkins, D.O., Dickel, D.E., Kusenda, M., Krastoshevsky, O., et al. (2009). 
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 41, 
1223-1227. 
Milad, M.R., and Quirk, G.J. (2002). Neurons in medial prefrontal cortex signal 
memory for fear extinction. Nature 420, 70-74. 
Milosevic, I., Giovedi, S., Lou, X., Raimondi, A., Collesi, C., Shen, H., Paradise, S., 
O'Toole, E., Ferguson, S., Cremona, O., et al. (2011). Recruitment of endophilin to 
77 
 
clathrin-coated pit necks is required for efficient vesicle uncoating after fission. 
Neuron 72, 587-601. 
Montague, P.R., Dayan, P., and Sejnowski, T.J. (1996). A framework for 
mesencephalic dopamine systems based on predictive Hebbian learning. J Neurosci 
16, 1936-1947. 
Mulherkar, S.A., and Jana, N.R. (2010). Loss of dopaminergic neurons and resulting 
behavioural deficits in mouse model of Angelman syndrome. Neurobiol Dis 40, 586-
592. 
Nair-Roberts, R.G., Chatelain-Badie, S.D., Benson, E., White-Cooper, H., Bolam, 
J.P., and Ungless, M.A. (2008). Stereological estimates of dopaminergic, GABAergic 
and glutamatergic neurons in the ventral tegmental area, substantia nigra and 
retrorubral field in the rat. Neuroscience 152, 1024-1031. 
Nicholls, R.D., and Knepper, J.L. (2001). Genome organization, function, and 
imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum 
Genet 2, 153-175. 
Olds, J., and Milner, P. (1954). Positive reinforcement produced by electrical 
stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47, 
419-427. 
Ostlund, S.B., Wassum, K.M., Murphy, N.P., Balleine, B.W., and Maidment, N.T. 
(2011). Extracellular dopamine levels in striatal subregions track shifts in motivation 
and response cost during instrumental conditioning. J Neurosci 31, 200-207. 
Philpot, B.D., Espinosa, J.S., and Bear, M.F. (2003). Evidence for altered NMDA 
receptor function as a basis for metaplasticity in visual cortex. J Neurosci 23, 5583-
5588. 
Portmann, T., Yang, M., Mao, R., Panagiotakos, G., Ellegood, J., Dolen, G., Bader, 
P.L., Grueter, B.A., Goold, C., Fisher, E., et al. (2014). Behavioral abnormalities and 
circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. 
Cell Rep 7, 1077-1092. 
Rice, M.E., and Cragg, S.J. (2008). Dopamine spillover after quantal release: 
rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58, 
303-313. 
Riday, T.T., Dankoski, E.C., Krouse, M.C., Fish, E.W., Walsh, P.L., Han, J.E., 
Hodge, C.W., Wightman, R.M., Philpot, B.D., and Malanga, C.J. (2012). Pathway-
specific dopaminergic deficits in a mouse model of Angelman syndrome. J Clin 
Invest 122, 4544-4554. 
78 
 
Robinson, D.L., Venton, B.J., Heien, M.L., and Wightman, R.M. (2003). Detecting 
subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clin Chem 
49, 1763-1773. 
Robinson, T.E., and Berridge, K.C. (1993). The neural basis of drug craving: an 
incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18, 247-291. 
Robison, A.J., and Nestler, E.J. (2011). Transcriptional and epigenetic mechanisms 
of addiction. Nat Rev Neurosci 12, 623-637. 
Rothwell, P.E., Fuccillo, M.V., Maxeiner, S., Hayton, S.J., Gokce, O., Lim, B.K., 
Fowler, S.C., Malenka, R.C., and Sudhof, T.C. (2014). Autism-associated neuroligin-
3 mutations commonly impair striatal circuits to boost repetitive behaviors. Cell 158, 
198-212. 
Russo, S.J., and Nestler, E.J. (2013). The brain reward circuitry in mood disorders. 
Nat Rev Neurosci 14, 609-625. 
Samaco, R.C., Mandel-Brehm, C., Chao, H.T., Ward, C.S., Fyffe-Maricich, S.L., 
Ren, J., Hyland, K., Thaller, C., Maricich, S.M., Humphreys, P., et al. (2009). Loss of 
MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter 
synthesis and specific behavioral abnormalities. Proc Natl Acad Sci U S A 106, 
21966-21971. 
Sato, M., and Stryker, M.P. (2010). Genomic imprinting of experience-dependent 
cortical plasticity by the ubiquitin ligase gene Ube3a. Proc Natl Acad Sci U S A 107, 
5611-5616. 
Sawaguchi, T., and Goldman-Rakic, P.S. (1994). The role of D1-dopamine receptor 
in working memory: local injections of dopamine antagonists into the prefrontal 
cortex of rhesus monkeys performing an oculomotor delayed-response task. J 
Neurophysiol 71, 515-528. 
Schultz, W. (1998). Predictive reward signal of dopamine neurons. J Neurophysiol 
80, 1-27. 
Schultz, W. (2007). Multiple dopamine functions at different time courses. Annu Rev 
Neurosci 30, 259-288. 
Seamans, J.K., and Yang, C.R. (2004). The principal features and mechanisms of 
dopamine modulation in the prefrontal cortex. Prog Neurobiol 74, 1-58. 
Shi, S.Q., Bichell, T.J., Ihrie, R.A., and Johnson, C.H. (2015). Ube3a imprinting 
impairs circadian robustness in Angelman syndrome models. Curr Biol 25, 537-545. 
Sidorov, M.S., Krueger, D.D., Taylor, M., Gisin, E., Osterweil, E.K., and Bear, M.F. 
(2014). Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 
knockout mice. Genes Brain Behav. 
79 
 
Sparta, D.R., Hovelso, N., Mason, A.O., Kantak, P.A., Ung, R.L., Decot, H.K., and 
Stuber, G.D. (2014). Activation of prefrontal cortical parvalbumin interneurons 
facilitates extinction of reward-seeking behavior. J Neurosci 34, 3699-3705. 
Sparta, D.R., Stamatakis, A.M., Phillips, J.L., Hovelso, N., van Zessen, R., and 
Stuber, G.D. (2012). Construction of implantable optical fibers for long-term 
optogenetic manipulation of neural circuits. Nat Protoc 7, 12-23. 
Stamatakis, A.M., Jennings, J.H., Ung, R.L., Blair, G.A., Weinberg, R.J., Neve, R.L., 
Boyce, F., Mattis, J., Ramakrishnan, C., Deisseroth, K., et al. (2013). A unique 
population of ventral tegmental area neurons inhibits the lateral habenula to promote 
reward. Neuron 80, 1039-1053. 
Stamatakis, A.M., and Stuber, G.D. (2012). Activation of lateral habenula inputs to 
the ventral midbrain promotes behavioral avoidance. Nat Neurosci 15, 1105-1107. 
Stuber, G.D., Hnasko, T.S., Britt, J.P., Edwards, R.H., and Bonci, A. (2010). 
Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum 
corelease glutamate. J Neurosci 30, 8229-8233. 
Surmeier, D.J., Ding, J., Day, M., Wang, Z., and Shen, W. (2007). D1 and D2 
dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium 
spiny neurons. Trends Neurosci 30, 228-235. 
Talis, A.L., Huibregtse, J.M., and Howley, P.M. (1998). The role of E6AP in the 
regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-
negative cells. J Biol Chem 273, 6439-6445. 
Tritsch, N.X., Ding, J.B., and Sabatini, B.L. (2012). Dopaminergic neurons inhibit 
striatal output through non-canonical release of GABA. Nature 490, 262-266. 
Tritsch, N.X., Oh, W.J., Gu, C., and Sabatini, B.L. (2014). Midbrain dopamine 
neurons sustain inhibitory transmission using plasma membrane uptake of GABA, 
not synthesis. Elife 3, e01936. 
Tsai, H.C., Zhang, F., Adamantidis, A., Stuber, G.D., Bonci, A., de Lecea, L., and 
Deisseroth, K. (2009). Phasic firing in dopaminergic neurons is sufficient for 
behavioral conditioning. Science 324, 1080-1084. 
Tye, K.M., Mirzabekov, J.J., Warden, M.R., Ferenczi, E.A., Tsai, H.C., Finkelstein, 
J., Kim, S.Y., Adhikari, A., Thompson, K.R., Andalman, A.S., et al. (2013). Dopamine 
neurons modulate neural encoding and expression of depression-related behaviour. 
Nature 493, 537-541. 
Wallace, M.L., Burette, A.C., Weinberg, R.J., and Philpot, B.D. (2012). Maternal loss 
of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific 
synaptic defects. Neuron 74, 793-800. 
80 
 
Walsh, J.J., and Han, M.H. (2014). The heterogeneity of ventral tegmental area 
neurons: Projection functions in a mood-related context. Neuroscience 282C, 101-
108. 
Williams, C.A., Beaudet, A.L., Clayton-Smith, J., Knoll, J.H., Kyllerman, M., Laan, 
L.A., Magenis, R.E., Moncla, A., Schinzel, A.A., Summers, J.A., et al. (2006). 
Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med 
Genet A 140, 413-418. 
Wise, R.A. (1978). Catecholamine theories of reward: a critical review. Brain Res 
152, 215-247. 
Wise, R.A., and Rompre, P.P. (1989). Brain dopamine and reward. Annu Rev 
Psychol 40, 191-225. 
Yamaguchi, T., Sheen, W., and Morales, M. (2007). Glutamatergic neurons are 
present in the rat ventral tegmental area. Eur J Neurosci 25, 106-118. 
Yamamoto, Y., Huibregtse, J.M., and Howley, P.M. (1997). The human E6-AP gene 
(UBE3A) encodes three potential protein isoforms generated by differential splicing. 
Genomics 41, 263-266. 
Yashiro, K., Riday, T.T., Condon, K.H., Roberts, A.C., Bernardo, D.R., Prakash, R., 
Weinberg, R.J., Ehlers, M.D., and Philpot, B.D. (2009). Ube3a is required for 
experience-dependent maturation of the neocortex. Nat Neurosci 12, 777-783. 
Yim, C.Y., and Mogenson, G.J. (1980). Electrophysiological studies of neurons in 
the ventral tegmental area of Tsai. Brain Res 181, 301-313. 
Zhang, S., Qi, J., Li, X., Wang, H.L., Britt, J.P., Hoffman, A.F., Bonci, A., Lupica, 
C.R., and Morales, M. (2015). Dopaminergic and glutamatergic microdomains in a 
subset of rodent mesoaccumbens axons. Nat Neurosci 18, 386-392. 
 
